

AHA SCIENTIFIC STATEMENT

Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention

A Scientific Statement From the American Heart Association

ABSTRACT: Cardiovascular disease (CVD) is the leading cause of death in women, who have a notable increase in the risk for this disease after menopause and typically develop coronary heart disease several years later than men. This observation led to the hypothesis that the menopause transition (MT) contributes to the increase in coronary heart disease risk. Over the past 20 years, longitudinal studies of women traversing menopause have contributed significantly to our understanding of the relationship between the MT and CVD risk. By following women over this period, researchers have been able to disentangle chronological and ovarian aging with respect to CVD risk. These studies have documented distinct patterns of sex hormone changes, as well as adverse alterations in body composition, lipids and lipoproteins, and measures of vascular health over the MT, which can increase a woman's risk of developing CVD postmenopausally. The reported findings underline the significance of the MT as a time of accelerating CVD risk, thereby emphasizing the importance of monitoring women's health during midlife, a critical window for implementing early intervention strategies to reduce CVD risk. Notably, the 2011 American Heart Association guidelines for CVD prevention in women (the latest sex-specific guidelines to date) did not include information now available about the contribution of the MT to increased CVD in women. Therefore, there is a crucial need to discuss the contemporary literature on menopause and CVD risk with the intent of increasing awareness of the significant adverse cardiometabolic health-related changes accompanying midlife and the MT. This scientific statement provides an up-to-date synthesis of the existing data on the MT and how it relates to CVD.

Samar R. El Khoudary, PhD, MPH, FAHA, Chair
Brooke Aggarwal, EdD, MS, FAHA
Theresa M. Beckie, PhD, FAHA
Howard N. Hodis, MD, FAHA
Amber E. Johnson, MD, MS, MBA
Robert D. Langer, MD, MPH, FAHA
Marian C. Limacher, MD, FAHA
JoAnn E. Manson, MD, DrPH, FAHA
Marcia L. Stefanick, PhD, FAHA
Matthew A. Allison, MD, MPH, FAHA, Vice Chair
On behalf of the American Heart Association
Prevention Science
Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing

Key Words: AHA Scientific Statements
■ estrogen ■ heart ■ intervention
■ lipids ■ menopause ■ menopause
hormone therapy ■ visceral fat

© 2020 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

Cardiovascular disease (CVD) is the leading cause of death in women.¹ According to the 2012 American Heart Association (AHA) survey of female awareness, knowledge, and perceptions related to CVD² and more recent data from 1011 US women (25–60 years of age) from the Women's Heart Alliance survey published in 2017, only 56% of women are aware of this fact.³

CVD AND MENOPAUSE

Women develop coronary heart disease (CHD) several years later than men, with a notable increase in CHD risk during midlife,⁴ a period coincident with the menopause transition (MT). This observation led to the hypothesis that the MT contributes to the increase in this risk.⁴

Over the past 20 years, longitudinal studies of women transitioning through menopause have contributed substantially to our understanding of the relationship between the MT and CVD risk. These studies have documented distinct patterns of alterations in endogenous sex hormones and adverse changes in body fat distribution, lipids, and lipoproteins, as well as structural and functional measures of vascular health over the MT.⁵ The reported findings underline the significance of the MT as a time of accelerating CVD risk, which emphasizes the importance of monitoring and potentially intervening during midlife.

GOAL OF THIS SCIENTIFIC STATEMENT

The latest 2011 AHA guidelines of CVD prevention in women⁶ did not incorporate the MT as a CVD risk factor. Therefore, there is a compelling need to discuss the implications of the accumulating body of literature on the MT and CVD risk. Therefore, the purpose of this scientific statement is to raise awareness of the significant adverse cardiometabolic health-related changes accompanying midlife and the MT. This statement highlights the complexity of the MT as a multidimensional transition during midlife and summarizes critical literature on the link between CVD risk and multiple menopause-related characteristics, beyond the dynamic hormonal alterations accompanying the MT. Moreover, the statement identifies critical cardiometabolic health changes relevant to the MT that are independent of chronological aging and reviews the current cardiovascular health status of midlife women using the AHA Life's Simple 7 components. Available evidence on effects of lifestyle interventions, as well as menopausal hormone therapy (MHT) use and lipid-lowering therapeutic options, on CVD risk is also discussed, with a particular focus on the timing of these interventions relevant to the MT. Finally, the implications of the evolving literature for

menopause-related changes in cardiometabolic health on current guidelines specific to preventing CVD in women are presented.

THE MENOPAUSE TRANSITION

Epidemiology of Menopause

Menopause signifies the permanent cessation of ovarian function and women's transition from a reproductive to a nonreproductive phase of life. It marks a critical stage characterized by remarkable changes in hormonal and menstruation patterns, as well as both physiological and psychosocial symptoms.

The experience of 12 consecutive months of amenorrhea not the result of other causes defines natural menopause.⁷ A 2018 published pooled analysis of 234 811 postmenopausal women from 17 cross-sectional and observational studies across 7 countries reported the median age at natural menopause to be 50.0 years (interquartile range, 48.0–53.0 years).⁸ Natural menopause is considered premature if it occurs before 40 years of age and early if it occurs between 40 and 45 years of age.⁹ Approximately 10% of women experience menopause before 45 years of age (1.9% before 40 years of age and 7.3% at 40–45 years of age).⁸ With the mean life expectancy at birth of 81 years for a US woman, many US women will spend up to 40% of their lives as postmenopausal.^{9,10}

Stages of Reproductive Aging

Reproductive aging includes 7 stages: 5 before and 2 after the final menstrual period (FMP; Figure 1).^{11–12c} Not all women will experience each of these 7 stages. Moreover, the duration of each of these stages varies between women, and each stage is characterized by variable changes in the menstruation pattern, hormonal levels, and menopause-related symptomatology, underscoring the complexity of studying the MT and its potential for health-related sequelae. The Stages of Reproductive Aging Workshop + 10¹² defined the MT as the time when a menstrual cycle becomes variable or other menopause-related symptoms begin until the time of the FMP (Figure 1).^{11–12c}

Depending on the menstrual cycle variability level, women could be classified as being in the early (a persistent difference in consecutive menstrual cycle length of at least 7 days) or the late (at least 60 days of amenorrhea experienced at least 1 time) transition stage. The perimenopause, which encompasses the most highly symptomatic years, begins with the onset of intermenstrual cycle irregularities (± 7 days) or other menopause-related symptoms and extends 12 months after menopause, thus persisting 1 year longer than the MT¹² (Figure 1).




Figure 1. The Stages of Reproductive Aging Workshop (STRAW) +10 staging system for reproductive aging in women.

STRAW defined 7 stages ranging from the onset of menstrual cycles at menarche and the reproductive age to the perimenopausal and postmenopausal phases. Principal (menstrual cycle), supportive (biochemical and imaging), and descriptive (symptoms) criteria are used to characterize the phases. AMH indicates anti-Müllerian hormone; FMP, final menstrual period; and FSH, follicle-stimulating hormone. *Blood drawn on cycle days 2 to 5. **Approximate expected level based on assays using current international pituitary standard. Reprinted from Davis et al¹¹ with permission from Springer Nature. Copyright © 2015, Macmillan Publishers Limited. Adapted from Harlow et al¹² with permission from The Endocrine Society, copyright © 2012, The Endocrine Society; from Harlow et al^{12a} with permission from Taylor & Francis Ltd, copyright © 2012, Taylor & Francis Ltd; from Harlow et al^{12b} with permission from the American Society for Reproductive Medicine, copyright © 2012, American Society for Reproductive Medicine, published by Elsevier Inc; and from Harlow et al^{12c} with permission, copyright © 2012, The North American Menopause Society.

As a standardized staging system for reproductive aging, the Stages of Reproductive Aging Workshop provides consistent classification of menopause stages across studies of midlife women, facilitating research to disentangle the health effects of ovarian and chronological aging. Moreover, this gold-standard staging system serves as a clinical tool for women and their healthcare providers, guiding fertility assessment, contraceptive needs, and decision making.¹²

Cardinal Hormonal Changes of the MT

The MT is characterized by dynamic changes in estradiol and follicle-stimulating hormone levels. Prospective studies of the MT, including SWAN (Study of Women's Health Across the Nation) and the Melbourne Women's Midlife Health Project, reported a decline in estradiol as early as 2 years before the FMP and a rise in follicle-stimulating hormone 6 years before this time point.¹³ However, not all women experience a uniform pattern of estradiol decline or follicle-stimulating hormone rise over the MT (Figure 2A and 2B).^{13,13a} That is, estradiol increases significantly 5.5 years before the FMP in 44.5% of midlife women, with a steep early decline almost 1 year before the FMP (estradiol rise–early decline) or a late estradiol decline after the FMP (estradiol rise–late decline). Two other common patterns of estradiol decline that are experienced by 55.5% of midlife women: a slow-decline

or a flat pattern (Figure 2A).¹³ Follicle-stimulating hormone rises in various degrees among midlife women (Figure 2B).¹³

Menopause-Related Symptomatology

As women traverse the MT, they may experience multiple symptoms such as hot flashes and night sweats (ie, vasomotor symptoms), mood changes (eg, depression and anxiety), and sleep and cognitive disturbances, as well as genitourinary and sexual function changes.^{14–19} Links between many of these symptoms and CVD risk have been found (see the Menopause Characteristics Relevant to CVD Risk section).

Vasomotor Symptoms

Vasomotor symptoms are the most common menopause-related symptoms (≈80% of midlife women) that affect a woman's quality of life and may require medical treatment. Vasomotor symptoms can last for 10 years, with a longer duration among women whose symptoms begin early in the MT. The timing and frequency of vasomotor symptoms vary over the MT, with 4 patterns having been identified: (1) early onset of vasomotor symptoms 11 years before FMP with a later decline, (2) onset near the FMP with a later decline, (3) persistently high frequency, and (4) persistently low frequency.^{14,15}

The cause of vasomotor symptoms seems to be multifactorial, with reproductive hormones playing an




Figure 2. Trajectories of estradiol (E2; A) and follicle-stimulating hormone (B) over the menopausal transition. Reprinted from El Khoudary and Thurston¹³ with permission from Elsevier. Copyright © 2018, Elsevier Inc. Adapted from Tepper et al,^{13a} by permission of Oxford University Press on behalf of the Endocrine Society.

integral role. Other factors found to be related to a higher occurrence and severity of vasomotor symptoms include obesity before menopause, cigarette smoking, higher levels of anxiety and depression, lower level of education, and premenopausal symptoms. Data on physical activity, diet, and alcohol consumption and their associations with vasomotor symptoms occurrence are not consistent.¹⁴

Sleep Disturbance

Sleep disturbance is a common complaint during the MT. Women report poorer sleep during the perimenopause

stage than the late reproductive age, with the severity of sleep-disordered breathing increasing as women transition from premenopause to postmenopause, independently of chronological aging or changes in body habitus.^{16,17} Recent analyses of longitudinal data from SWAN (n=1258 midlife women) showed that only 15% of midlife women report increasing sleep complaints (waking up frequently) during perimenopause, and the remainder experience a stable increase in sleep complaints consistent with an aging-related increase in sleep problems not specific to menopause.¹⁸ Vasomotor symptoms, hormonal changes, comorbid conditions,

Downloaded from <http://ahajournals.org> by on May 21, 2024

obesity, and psychosocial factors have been linked to increased sleep disturbances during the MT.^{15,16}

Depression and Anxiety

Well-designed longitudinal studies of clinical depression reported 2- to 5-fold higher risk for major depressive episodes during perimenopause compared with late premenopause.^{15,19} Moreover, midlife women are more likely to experience anxiety symptoms over the MT, which peak during late perimenopause. Both depression and anxiety symptoms tend to decline after menopause.^{15,19}

Factors Influencing Natural Menopause Timing

Age at natural menopause is viewed as a marker of not only reproductive aging but also somatic aging and general health. Later age at natural menopause has been linked to a longer life expectancy, higher bone mineral density and lower risk of fracture, and reduced all-cause mortality, CVD, and cardiovascular death, yet greater breast (among obese) and ovarian cancer risk.^{20–26}

Race/Ethnicity

Results from studies testing whether the timing of natural menopause differs by race/ethnicity are inconsistent.^{27–31} Compared with non-Hispanic White women, Japanese American women may experience menopause at a later age,^{28,29} whereas Hispanic,^{28,29} Native Hawaiian,²⁸ and Black³⁰ women may experience menopause at a relatively younger age. These differences may be driven by variations in socioeconomic, lifestyle, and health factors.³¹

Reproductive History Factors

A number of factors have been implicated in the timing of natural menopause. Women with an average cycle length of <26 days, consistent with faster follicle depletion, may reach menopause 1.4 years earlier than women with longer cycles.³² On the other hand, studies associating menstrual cycle irregularity with age at natural menopause provide inconclusive results,^{30,33,34} whereas higher parity has consistently been linked to a later age at natural menopause.^{27,30,33–36} Several studies did not show an association between age at menarche and age at menopause after adjustment for parity and cycle length.²⁷ However, a recent pooled analysis across 9 cohorts associated early age at menarche (≤ 11 years) with 80% increased risk of premature and 32% increased risk of early menopause, and the risk doubled in nulliparous women.³⁵ Data on oral contraceptive use are not conclusive.^{27,29,33,37}

Weight and Body Mass

Several studies reported a positive association between premenopausal weight, higher body mass index (BMI)

and waist-to-hip ratio, and later age at natural menopause.^{31,33,34} Conversely, other studies showed that women who are underweight in early or midadulthood or have low BMI have elevated risk for early menopause.^{28,36,38} However, other studies failed to show a similar association.^{29,30,37,39} Most recently, cross-trait linkage disequilibrium score regression analyses showed significant negative genetic correlations between age at natural menopause and BMI, weight, and waist and hip circumference, suggesting a genetic pleiotropy (eg, genetic variants associated with both earlier age at menopause and traditional CVD risk factors).^{40,41}

Premenopausal Cardiovascular Health

Although menopause timing is hypothesized to contribute to CVD risk, the associations may be bidirectional. That is, data from the Framingham Heart Study showed that higher total cholesterol, systolic blood pressure (SBP) and diastolic blood pressure (DBP), and other cardiovascular risk factors before menopause were associated with earlier menopause, independently of smoking status.⁴² In addition, in a pooled analysis of 177 131 women from 9 studies, a first CVD event before 35 years of age was associated with a doubling of the risk of an early menopause, whereas a first event occurring after 35 years of age was associated with menopause at 51 years of age.⁴³ It is thus possible that worse premenopausal cardiovascular health could influence the onset of natural menopause.⁴²

Physical Activity, Diet, and Alcohol Consumption

Physical activity is associated with lower concentrations of reproductive hormones and frequency of ovulation and therefore could potentially be associated with a later age at natural menopause.²⁷ However, results are not consistent.^{30,31,33,36,37,44}

Most dietary patterns and individual dietary components have not been consistently linked to earlier or later age at menopause.^{33,36,37,45–47} A 2016 systematic review and meta-analysis of 22 articles from 20 unique studies on the association between alcohol intake and onset of menopause showed that low and moderate alcohol consumption might be associated with later onset of menopause, although the magnitude of the reported association was low.⁴⁸

Cigarette Smoking

A 2008 published systematic review of 109 studies confirmed a link between cigarette smoking and earlier age at natural menopause.⁴⁹ Women who smoke are likely to undergo natural menopause ≈ 1 year earlier than nonsmokers.²⁷ A recent pooled analyses of >220 000 postmenopausal women from 17 studies across 7 countries revealed that higher intensity, longer duration, higher cumulative dose, earlier age at starting smoking, and shorter time since quitting smoking

are associated with greater risk of premature and early menopause among both current and former smokers.⁸

Genetics

Evidence suggests that the age at menopause is a complex genetic trait with a wide estimate of heritability that ranges from 31% to 87%.⁵⁰ Genome-wide association studies have implicated common genetic loci affecting several potential gene candidates across multiple molecular pathways, including DNA repair, immune function, and neuroendocrine pathways of ovarian function.^{40,41,51–54} Moreover, epigenetic studies suggest that early age at menopause is associated with blood DNA methylation patterns linked to accelerated aging (the epigenetic clock), supporting some coheritability between age at natural menopause and epigenetic age acceleration.⁵⁵ These findings suggest shared molecular pathways between ovarian and somatic aging that may explain how menopause timing could affect aging of different body systems, including the cardiovascular system.

MENOPAUSE CHARACTERISTICS RELEVANT TO CVD RISK

Several MT characteristics have been evaluated in relation to CVD risk. These include age at menopause, type of menopause, menopause stages, endogenous estradiol, and menopause-related symptoms.

Age at Natural Menopause

A 2016 pooled meta-analysis of 32 observational studies of 310 329 nonoverlapping women reported that, compared with women with menopause at ≥ 45 years of age, women with early-onset menopause (< 45 years of age) had a significantly higher risk of overall (relative risk [RR], 1.50 [95% CI, 1.28–1.76]) and fatal (RR, 1.11 [95% CI, 1.03–1.20]) CHD, even after adjustment for established CVD risk factors. In addition, women experiencing menopause at 50 to 54 years of age had a lower RR of fatal CHD than those with menopause before 50 years of age (RR, 0.87 [95% CI, 0.80–0.96]).²³ Other studies have reported similar findings.⁵⁶

In a meta-analysis pooling data from 3 prospective studies that included 3568 heart failure events, compared with women with later onset of menopause, women who experienced early menopause (at < 45 years of age) had a significantly greater risk of heart failure (hazard ratio [HR], 1.33 [95% CI, 1.15–1.53]).⁵⁷

Some evidence suggests a reverse association between age at natural menopause and total CVD risk.^{58,59} Among 1684 women ≥ 65 years of age at baseline from the Iowa PESE (Iowa Established Populations for the Epidemiological Study of the Elderly), later age at natural menopause (≥ 55 years) was related to increased

all-cause and cardiovascular mortality.⁵⁹ However, these results are contrary to those from the EPIC-CVD case-cohort study (European Prospective Investigation Into Cancer and Nutrition–CVD) of 15 402 European women 35 to 70 years of age at baseline, which reported an inverse dose-response relationship (continuous and approximately linear across the menopausal age range) between age at menopause and CHD risk (adjusted HR, 1.02 [95% CI, 1.01–1.03] per 1-year decrease).⁶⁰

Type of Menopause

Previous studies suggest that CHD risk varies by type of menopause, with risk being higher for menopause caused by bilateral oophorectomy (BSO) with no estrogen therapy use than for natural menopause.⁶¹ A 2007 review underscored the importance of assessing this risk in the setting of age at surgery relative to the timing of natural menopause.⁶² In this report, hysterectomy without BSO was not associated with increased CVD risk, whereas there was little to no association between BSO and CVD risk when BSO occurred around the time of natural menopause. However, CHD risk was substantially higher when BSO occurred at a younger age (< 40 – 45 years).⁶² Other studies have found similar results.^{60,63} According to a large cohort study of 144 260 postmenopausal women in the United Kingdom, the risk for composite CVD among women with BSO before 40 years of age did not differ from that in women with premature natural menopause (< 40 years).⁶⁴

In an effort to understand mechanistic pathways by which surgical menopause might increase CHD risk compared with natural menopause, researchers assessed changes in CVD risk factors from before to after surgery and changes from before to after natural menopause.^{65,66} In a longitudinal analysis from the SWAN study of nearly 2000 women observed over 9 years across the FMP or age at surgery, hysterectomy with or without ovarian conservation was not a key determinant of CVD risk factor status either before or after elective surgery in midlife.⁶⁵ Findings from CARDIA (Coronary Artery Risk Development in Young Adults Study) are similar.⁶⁶

Menopause Stages

A cross-sectional analysis of a Korean cohort of 2037 women 44 to 56 years of age at different stages of the MT (premenopause, early and late MT, and postmenopause; see The MT section) reported significantly higher SBP and DBP only in late versus early MT,⁶⁷ whereas a longitudinal SWAN analysis found that total cholesterol, high-density lipoprotein (HDL) cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and lipoprotein(a) peaked during late perimenopause and early postmenopause, with a relative

odds of 2.1 (95% CI, 1.5–2.9 for an LDL-C \geq 130 mg/dL) during the early postmenopausal compared with premenopausal stages.⁶⁸

Metrics of vascular health also have been evaluated in relation to menopause stages. Progression rates of carotid intima-media thickness (cIMT) and adventitial diameter differed by menopause stage in a longitudinal SWAN analysis of repeated carotid scan measures over the MT, with structural carotid artery remodeling being most evident during the late perimenopausal stage compared with the premenopausal and early perimenopausal stages.⁶⁹ A later SWAN study reported that midlife women undergoing the MT had more rapid increases in aortic pulse wave velocity than women who remained premenopausal or were postmenopausal throughout an average of 2.3 years of follow-up.⁷⁰

Endogenous Estrogens

Declining endogenous estradiol levels during the MT also have been associated with a wide range of cardiovascular risk factor changes. However, this literature has been limited by cross-sectional design and an overemphasis on postmenopausal women, thereby yielding complex and inconsistent associations.¹³ In contrast, results from studies linking estradiol with subclinical measures of atherosclerosis have been more consistent. For example, in cross-sectional analyses of late perimenopausal and postmenopausal women, higher estradiol levels were related to a smaller carotid interadventitial diameter (suggesting less carotid remodeling), whereas higher estrone levels were related to a higher brachial flow-mediated dilation (ie, better endothelial function).⁷¹ SWAN also reported an association between higher estradiol levels and lower progression of carotid interadventitial diameter over time.⁷² Different associations were seen when trajectories of estradiol over the FMP were evaluated (Figure 2A). Specifically, compared with women with low estradiol before and after their FMP, SWAN participants with higher estradiol before their FMP but lower estradiol thereafter appeared to be less likely to develop carotid plaque after menopause.⁷³

Vasomotor Symptoms

Vasomotor symptoms reported at midlife have been linked to an adverse lipid profile, insulin resistance, and greater risk for incident hypertension.^{13,15} A cross-sectional SWAN analysis reported that women with hot flashes had reduced flow-mediated dilation and greater aortic calcification, independently of CVD risk factors and estradiol, compared with women reporting no hot flashes.⁷⁴ In a SWAN ancillary study, women who reported hot flashes at both baseline and follow-up visits, which were 2 years apart, had higher cIMT than those

reporting no hot flashes, particularly among women who were overweight or obese.⁷⁵

Some research indicates that vasomotor symptoms–CVD risk associations may be sensitive to the timing or duration of vasomotor symptoms. In a longitudinal SWAN analysis exploring trajectories of vasomotor symptoms, women with vasomotor symptoms early in the MT had higher mean and maximal cIMT than those with consistently low frequency of vasomotor symptoms across the transition.⁷⁶ A link between vasomotor symptoms and the development of CVD has also been reported. In this respect, a meta-analysis of 10 studies that included 213 976 women with a total of 10 037 CVD outcomes compared women with and without any menopausal symptoms reported that the presence of vasomotor symptoms and other menopausal symptoms was generally associated with increased risk of CHD, stroke, or CVD. Notably, only the association between menopausal symptoms and CHD persisted after adjustment for established CVD risk factors (RR, 1.28 [95% CI, 1.08–1.52]).⁷⁷

Sleep Disturbance

Cross-sectional studies of women at different stages of the MT showed significant associations of objective measures of poorer sleep quality with greater risk of metabolic syndrome⁷⁸ and both carotid plaque and cIMT.⁷⁹ Self-reported poor sleep quality has been independently linked to a greater risk of aortic calcification in midlife women⁸⁰ and to higher arterial stiffness in perimenopausal, but not premenopausal, women.⁸¹ In a recent exploratory analysis of the impact of menopause status on associations between subjective measures of sleep quality and cardiovascular health, as measured by the AHA Life's Simple 7 score, shorter sleep duration, poorer sleep quality, and greater severity of insomnia were associated with worse AHA Life's Simple 7 scores in postmenopausal, but not premenopausal, women.⁸²

Depression

Depressive symptoms during the MT also have been strongly linked to increased CVD risk.^{83–85} In healthy women 46 to 59 years of age in the SWAN Heart Study followed up for 5 years, having \geq 3 versus no episodes of depression was significantly associated with elevated coronary artery calcification scores.⁸⁴ Among postmenopausal women enrolled in the WHI trials (Women's Health Initiative) with no history of CVD and followed up for an average of 4.1 years, depression was an independent predictor of CVD death and all-cause mortality after adjustment for demographics and established risk factors for CVD.⁸⁵

CARDIOMETABOLIC HEALTH CHANGES ACCOMPANYING THE MT BEYOND CHRONOLOGICAL AGING

As discussed below, key cohort studies, including SWAN,^{69,72,86,87} the Melbourne Women's Midlife Health Project,^{88–90} the Healthy Women Study,⁹¹ the Penn Ovarian Aging Study,⁹² and the Seattle Women's Health Study,⁹³ were specifically designed to address relative contributions of chronological and reproductive aging to cardiometabolic health. The Atherosclerosis Risk in Communities cohort,⁹⁴ the Nurses' Health Study II,⁹⁵ and other prospective cohorts,^{96–99} although not designed for this primary purpose, have also offered important insights. In their efforts to disentangle the contribution of the MT beyond aging, longitudinal studies analyzed health measures anchored to time elapsed since menopause and tested whether a linear or a piecewise model better fit the analyzed data. The linear model was consistent with chronological aging, whereas the piecewise linear model suggested ovarian aging.

Lipids, Blood Pressure, Insulin, Glucose, and the Metabolic Syndrome

The SWAN study provided some of the strongest evidence on reproductive aging and changes in lipids, demonstrating that several lipid parameters (total cholesterol, LDL-C, and apolipoprotein B levels) increase dramatically within a relatively brief time span (from the year before to the year after the FMP) and that these associations were independent of the effect of aging alone.^{86,100} On the other hand, HDL-C levels were found to have a complex relationship with menopause, with the quality or functional capacity of HDL undergoing alterations.¹⁰¹ More specifically, the MT is associated with an apparent reversal in the direction of the association between HDL-C and CVD risk, with higher HDL-C levels associated with less carotid atherosclerosis before menopause but with greater carotid atherosclerosis after menopause.¹⁰² The HDL changes observed during the MT include changes in HDL particle distribution and function. Moreover, preliminary work from SWAN suggests that a key antiatherogenic function of HDL particles,¹⁰³ the ability to promote the first step in the reverse cholesterol transport, may weaken during the MT.

Although menopause was not independently linked to increases in blood pressure, insulin, or glucose beyond age,^{86,90} the prevalence of the metabolic syndrome (and the clustering of its components) appeared to increase with menopause, beyond the effects of chronological aging.^{87,100,104} These associations have generally been consistent across cohort studies.^{87,89,92,94} Moreover, a report from the Atherosclerosis Risk in Communities cohort documented that the progression and increase in severity of the metabolic syndrome were greatest

during the late premenopausal and perimenopausal years rather than during the postmenopausal period ($P < 0.05$).⁹⁴ The rate of change in metabolic syndrome severity during this reproductive stage was more pronounced in Black women than in White women in the cohort ($P < 0.0001$ and $P = 0.036$, respectively).⁹⁴

Vascular Health Measures

Beyond changes in cardiometabolic risk factors, vascular imaging studies have shown adverse changes during the MT that extend beyond the effects of aging. In a longitudinal analysis from a SWAN ancillary study, marked increases in carotid atherosclerosis (eg, increases in cIMT and carotid adventitial diameter) were found during late perimenopause relative to premenopause that were independent of aging.⁶⁹ Most recently, a significant increase was reported in arterial stiffness (percent increase, 7.5% [95% CI, 4.1–11.1]), measured via carotid femoral pulse wave velocity, within 1 year of the FMP in SWAN participants, which was not explained by adjustment for traditional CVD risk factors.¹⁰⁵

Weight Gain, Body Composition, and Ectopic Fat

Midlife weight gain, often accompanied by reduced energy expenditure, can be explained largely by changes in chronological age.⁹¹ In SWAN, there was no difference in self-reported weight (or BMI) among premenopausal versus postmenopausal women after adjustment for age.¹⁰⁶ In both SWAN and the Healthy Women Study, change in body weight was prospectively assessed during the MT. In both studies and over the 3-year period, women gained an average of ≈ 2.0 to 2.3 kg, but these differences were not related to menopausal status.^{91,100,106}

Although weight change was more closely related to chronological than reproductive aging, the MT was found to be independently associated with adverse changes in body composition and increases in visceral adipose tissue.¹⁰⁰ Using dual energy x-ray absorptiometry, SWAN investigators examined change in body composition over 18 years across the FMP (8 years before and 10 years after the FMP). Of note, ≈ 2 years before the FMP, the rate of fat gain doubled and lean mass declined, which continued until 2 years after the FMP, suggesting that accelerated gains in fat mass and losses of lean mass are menopause-related phenomena.¹⁰⁷ In a study of 23 women who underwent MRI assessments of body composition when they were premenopausal and then ≈ 8 years later when they were postmenopausal, there were statistically significant increases in total abdominal fat, subcutaneous adipose tissue, and visceral adipose tissue but no significant changes in weight, waist circumference, or

lean mass after adjustment for age.¹⁰⁸ Other studies have had similar findings.^{109–111} Ectopic fat deposition, defined as the accumulation of excess adipose tissue in organs such as the heart and liver, may relate to the MT. Research involving imaging of intrathoracic adiposity has suggested a link between paracardial fat depositions (the fat outside the parietal layer of the pericardium) with menopause and lower endogenous estradiol levels that are independent of age. Fat deposition around the heart may be particularly deleterious, given its close proximity to the myocardium and role in secreting inflammatory cytokines.¹¹² Indeed, mounting evidence supports its link with CVD risk,¹¹³ as well as greater accumulations during late perimenopause and postmenopause compared with the premenopausal period, independently of age and other potential confounders.¹¹⁴ New research from the KEEPS trial (Kronos Early Estrogen Prevention Study) of MHT use and atherosclerosis progression in recently menopausal women demonstrated a differential effect of MHT (based on the type of agent used or route of administration) on heart fat deposition¹¹⁵ and its association with both coronary artery calcification¹¹⁵ and cIMT.¹¹⁶

Compared with premenopausal women, postmenopausal women may be at a greater risk of fat deposition in the liver, although the literature has not been consistent.^{117–120} An overnourished zebrafish model has shown that ovarian senescence triggers the development of hepatic steatosis and the fibrotic progression of liver disease,¹¹⁸ suggesting that menopause-related hormonal changes contribute to fat accumulation in liver after menopause. However, a number of studies linking years from menopause¹¹⁹ and timing of menopause (early [<45 years of age], normal [45–54 years of age], and late [≥ 55 years of age] postmenopause)¹²⁰ with risk of nonalcoholic fatty liver disease do not support this link.

WOMEN'S CARDIOVASCULAR HEALTH (LIFE'S SIMPLE 7) AT MIDLIFE: CURRENT STATUS

The AHA operationalizes cardiovascular health (referred to as Life's Simple 7) as ideal, intermediate, or poor according to 7 core health indicators: BMI, physical activity, smoking, diet, cholesterol, blood pressure, and fasting glucose.¹²¹ At any age, women tend to have more metrics at ideal levels than men, yet only one-fifth of women ≥ 20 years of age have ≥ 5 metrics of ideal cardiovascular health according to the National Center for Health Statistics and NHANES (National Health and Nutrition Examination Survey) 2013 to 2014.¹ Data characterizing the current status of metrics of cardiovascular health in women transitioning through menopause

are limited. Thus, data from postmenopausal women were presented as appropriate.

BMI and Adiposity

More than 42% of US women 40 to 59 years of age have a BMI ≥ 30 kg/m².^{1,122} The age-adjusted prevalence of obesity is higher among middle-aged women (40–59 years of age, 42.1%) than younger women (20–39 years of age, 34.4%).¹²³

In postmenopausal women with a BMI ≥ 40 kg/m², a waist circumference of 115.5 to 122 and >122 cm, compared with ≤ 108.4 cm, was associated with higher total mortality and incidence of both CHD and heart failure.¹²⁴ Moreover, postmenopausal women who had normal BMI with higher central adiposity (defined as waist circumference ≥ 88 cm) were at higher risk of mortality than those with normal BMI and no central adiposity.¹²⁵

Physical Activity and Sedentary Behavior

Evidence demonstrates a strong inverse dose-response association between amount of physical activity and cardiovascular mortality.¹²⁶ Current recommendations encourage women to engage in ≥ 150 min/wk of moderate-intensity aerobic (or 75 min/wk of vigorous) physical activity.¹²⁷ Notably, only 7.2% of midlife women from the SWAN study self-reported physical activity levels that consistently met the current recommendations.¹²⁸ Among adults 20 to 59 years of age, 3.2% of women and 3.8% of men met recommendations to engage in moderate to vigorous physical activity for 30 minutes (in sessions of ≥ 10 minutes) on ≥ 5 of 7 days.¹ For objectively measured (eg, by accelerometer) moderate to vigorous physical activity, adherence to physical activity recommendations was 2.3% among women ≥ 60 years of age and 2.5% for men of the same age.¹

A systematic review found that the association between sedentary behavior and all-cause mortality and CVD mortality was nonlinear.¹²⁹ Specifically, the risk for all-cause and CVD mortality risk increased more rapidly with >8 h/d of sedentary behavior.

Cigarette Smoking

Currently, $\approx 13.5\%$ of adult women are smokers.¹ Conversely, data from the SWAN study showed that 62.2% of the study participants never smoked and remained in this status over time.¹²⁸ On the basis of age-adjusted estimates in 2015, among people ≥ 65 years of age, 9.7% of men and 8.3% of women were current smokers.¹

Women who smoke die ≈ 11 years earlier than women who have never smoked.¹³⁰ A meta-analysis of prospective cohort studies suggests that the relative risk of CHD from smoking 1 cigarette per day is higher in

women than in men.¹³¹ Compared with women who never smoked, women who smoke have an increased risk of CHD and stroke incidence, as well as mortality from CHD and all causes.¹³²

Diet

In a recent analysis from the SWAN study, only 17.8% of study participants consistently stayed in the top tertile of the alternate Healthy Eating Index, a well-established scale to quantify diet quality in 9 nutrient components (vegetables, fruit, nuts, white to red meat consumption, cereal fiber, *trans* fat, ratio of polyunsaturated/saturated fatty acids, multivitamins, alcohol consumption), with higher values indicating higher-quality diet, over the MT.¹²⁸ In the Netherlands Epidemiology of Obesity study, a prospective cohort study of 6671 individuals 45 to 65 years of age, dietary intake of fruit and vegetables and plant-based fats and oils was associated with less visceral fat, and intake of sweet snacks was associated with more liver fat.¹³³ More than half of the 3576 women in the study were postmenopausal.

Cholesterol

Among US adults ≥ 60 years of age, only 25.2% have a total cholesterol level < 200 mg/dL.¹ The prevalence of LDL-C ≥ 130 among women ≥ 20 years of age is 30.4%. Some variation in mean LDL-C levels is noted between racial/ethnic groups of women, with the highest mean LDL-C levels for non-Hispanic White women at 114.9 mg/dL compared with 112.1 mg/dL for men. The mean LDL-C levels for women were 111.4 mg/dL for non-Hispanic Black women, 112.6 mg/dL for Hispanic women, and 110.3 mg/dL for non-Hispanic Asian women.¹

Blood Pressure

Hypertension remains the most prominent modifiable CVD risk factor that increases with age among women.^{134,135} Although a higher percentage of men had hypertension before 65 years of age (NHANES data 2013–2016), a higher percentage of women had hypertension thereafter, with the gap between men and women reaching its nadir at ≈ 55 to 64 years of age.¹ Women > 60 years of age are less likely to have controlled blood pressure (49.2%) compared with younger women (40–49 years of age, 54.2%; 18–39 years of age, 62.6%).¹³⁶ According to NHANES 2010 to 2016 data among adults ≥ 20 years of age, 38.8% of non-Hispanic White women, 53.2% of non-Hispanic Black women, and 37.9% of Hispanic women had hypertension.¹ Pooled data from 124 prospective cohort studies that included 1.2 million individuals, of whom 44% were women, found that, after controlling for comorbidities, every 10-mmHg increase in SBP was

associated with a 15% increased risk of CVD for both men and women.¹³⁷

Fasting Glucose

Diabetes is a stronger risk factor for CVD mortality in women than in men,^{138,139} and some evidence suggests a link between menopause and higher risk of type 2 diabetes.¹⁴⁰ In a pooled analysis of $> 850\,000$ participants with diabetes, the risk of CVD was 44% greater in women compared with men.¹⁴¹ Unfortunately, the prevalence of diabetes has increased significantly for both men and women over the past 2 decades. Clinically diagnosed diabetes was reported in 5.4% of both men and women ≥ 20 years of age in the 1988 to 1994 NHANES survey and in 10.9% of men and 8.9% of women in the 2013 to 2016 survey.¹

EFFECT OF LIFESTYLE INTERVENTIONS ON CARDIOMETABOLIC HEALTH AND CVD RISK IN MIDLIFE WOMEN: INTERVENTION TIMING

To achieve ideal cardiovascular health, as presented in the 2011 AHA's classification of CVD risk in Women and Life's Simple 7,^{6,121,142} lifestyle interventions should bring about smoking cessation in smokers, weight loss in overweight women, a DASH (Dietary Approaches to Stop Hypertension)-like eating pattern,^{143,144} physical activity to recommended levels,¹²⁷ and optimization of total cholesterol, fasting blood glucose, and blood pressure levels.^{145,146} Strong lines of evidence support the critical contribution of controlling these factors in reducing CVD burden. However, very limited research has focused on the timing of lifestyle interventions as related to the MT, when women are subjected to multiple adverse changes in several cardiometabolic health parameters simultaneously (see the Cardiometabolic Health Changes Accompanying the MT Beyond Chronological Aging section).

Randomized Clinical Trials of Lifestyle Interventions on Cardiometabolic Health in Women's Transition Through Menopause

Early randomized clinical trials (RCTs) examining the potential cardiovascular benefits of diet and exercise interventions in middle-aged women, including the SWCP-II (second Stanford Weight Control Project)¹⁴⁷ and the DEER trial (Diet and Exercise for Elevated Risk),¹⁴⁸ intentionally included or excluded participants by menopausal status. Both trials found significant lipid profile improvements and reduced central obesity

from a reduced-fat (total and saturated) diet combined with increased physical activity.^{147,148} Of note, these trials recruited women with different baseline lipid profiles and different phases of the MT. Therefore, any differences in the intervention effects on cardiovascular risk could not be directly attributed to differences in menopausal status.

The Pittsburgh WHLP (Women's Healthy Lifestyle Project) was probably the first and, to date, is the only RCT designed specifically to assess the effects of a diet and exercise intervention during the MT.¹⁴⁹ The WHLP trial randomized 535 healthy premenopausal women 44 to 50 years of age to an assessment-only control group or a 5-year cognitive-behavioral program that included a hypocaloric diet with reduced saturated fat and cholesterol combined with moderately increased leisure-time physical activity. An LDL-C increase in the control group during perimenopause to postmenopause was blunted in the intervention group. In addition, the intervention prevented weight gain from premenopause to perimenopause to postmenopause and reduced triglycerides, SBP, DBP, and blood glucose and insulin.¹⁴⁹ MHT use did not modify the associations between treatment groups and changes in LDL-C and other CHD risk factors. In addition, the intervention slowed cIMT progression among perimenopausal/postmenopausal (0.008 mm/y for the control group versus 0.004 mm/y for the intervention group; $P=0.02$), whereas no differences were seen in premenopausal women.¹⁵⁰

Most lifestyle intervention trials of cardiovascular risk factors in middle-aged (between 40 or 45 and 64 years or up to 69 years of age) women published since the WHLP trial have also distinguished between premenopausal and postmenopausal women, with the specific intention of not including women in the MT. For example, a small single-arm (diet and physical activity) weight loss intervention study showed significantly fewer changes in metabolic risk factors between 22 premenopausal women (mean±SD age, 43.7±6.4 years) and 50 postmenopausal women (mean±SD age, 58.2±5.1 years).¹⁵¹ Moreover, in a 2018 systematic review and meta-analysis of 17 small RCTs (a total of 792 women) on the effects of exercise on body composition, cardiovascular risk factors, and bone mineral density among menopausal women, exercise exerted significant benefits on body fat, waist circumference, and triglyceride levels. Of note, all participants were postmenopausal.¹⁵²

We were unsuccessful in finding lifestyle RCTs that recruited participants or stratified randomization by menopausal stage or other menopausal characteristics associated with greater cardiovascular risk such as early age of menopause or vasomotor symptoms, discussed in the Menopause Characteristics Relevant to CVD Risk

and Cardiometabolic Health Changes Accompanying the MT Beyond Chronological Aging sections.

Lifestyle Behaviors and Cardiometabolic Health in Midlife Women

With the growing body of literature supporting an acceleration of CVD risk and associated factors as women transition through menopause (Menopause Characteristics Relevant to CVD Risk and Cardiometabolic Health Changes Accompanying the MT Beyond Chronological Aging sections), increasing efforts have been directed at testing associations between healthy lifestyle behaviors and CVD risk in women in the observational study setting. The Nurses' Health Study provided some of the strongest and earliest evidence of the benefit of adherence to a healthy lifestyle, including diet, exercise, and abstinence from cigarette smoking, in reducing CHD risk in women.¹⁵³ Women who adhered to multiple healthy lifestyle parameters over 14 years of follow-up (only 3% of the study population) had an RR of coronary events of 0.17 (95% CI, 0.07–0.41) compared with all other women.¹⁵³

A recent large systematic review and meta-analysis of 59 prospective cohort studies involving >5.3 million middle-aged and elderly (not defined) women evaluated associations between modifiable lifestyle factors and fatal and nonfatal CVD events.¹³² In a comparison of women who currently smoked and never smokers, the pooled reduced risks were 3.12 (95% CI, 2.15–4.52) for CHD incidence, 2.09 (95% CI, 1.51–2.89) for stroke incidence, and 2.76 (95% CI, 1.62–4.71) for CVD mortality.¹³² Studies comparing the effects of cigarette smoking cessation in perimenopausal and postmenopausal women with premenopausal women on CVD-related outcomes are rare.¹⁵⁴

In the same meta-analysis described above, both lower BMI and greater leisure physical activity were associated with lower CVD risk.¹³² Specifically, compared with women with a BMI <25 kg/m², CHD risk increased from 1.47 (95% CI, 1.20–1.81) for a BMI of 25 to 30 kg/m² to 1.67 (95% CI, 1.24–2.25) for a BMI of 30 to 35 kg/m². Moreover, women who reported leisure physical activity had a reduced risk of CHD (0.71 [95% CI, 0.67–0.75]), stroke (0.77 [95% CI, 0.70–0.85]), and CVD mortality (0.70 [95% CI, 0.58–0.84]).¹³²

Despite voluminous literature showing that weight-reducing dietary changes may reduce CVD risk in obese adults,^{143,155,156} we are unaware of a meta-analysis focusing on CVD risk in middle-aged women for a healthy eating pattern that emphasizes fruits, vegetables, and low-fat dairy products and reduced saturated fatty acids, red meat, sweets, and beverages containing added sugars and includes whole grains, poultry, fish, and nuts.

In 1143 participants, the SWAN study prospectively tested associations of a composite healthy lifestyle score, constructed from self-reported data on cigarette smoking, diet, and physical activity, and subclinical atherosclerosis as common cIMT and interadventitial diameter, measured 14 years after baseline.¹²⁸ Compared with women in the lowest score level, those in the highest score level (indicating healthier lifestyle) had 0.024-mm-thinner cIMT (95% CI, -0.048 to 0.00) and 0.16-mm-smaller interadventitial diameter (95% CI, -0.27 to -0.04). Abstinence from cigarette smoking showed the strongest inverse associations with measures of subclinical carotid atherosclerosis (never smokers had 0.047-mm thinner-cIMT [95% CI, -0.07 to -0.024] and 0.24-mm-smaller interadventitial diameter [95% CI, -0.35 to -0.13]) and 49% lower odds of higher carotid artery plaque risk (odds ratio, 0.51 [95% CI, 0.35–0.73]) compared with those who smoked during follow-up.¹²⁸

In another SWAN study that included 721 midlife women with prevalent metabolic syndrome at baseline, reversal of metabolic syndrome was observed in 16.7% of the included women. Eating fewer calories over the MT (HR, 0.96 [95% CI, 0.93–0.990] per 100 kcal) was associated with this reversal, whereas physical activity was associated with 60% lower risk of developing metabolic syndrome among 493 women without metabolic syndrome at baseline in the same study.¹⁵⁷

EFFECTS OF MENOPAUSAL HORMONE THERAPY USE ON CARDIOMETABOLIC HEALTH AND CVD EVENTS

All high-quality evidence to date on the effects of MHT use on cardiometabolic health is based on clinical trials conducted among postmenopausal women. No data are available on the effects of MHT use on cardiometabolic health in women during perimenopause, who may need to use MHT to treat MT-related symptomatology. In fact, US Food and Drug Administration guidance on clinical trial design for new products to be approved for treating vasomotor symptoms recommends including only postmenopausal women, defined as those with 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels >40 mIU/mL or women 6 weeks after BSO with or without hysterectomy.¹⁵⁸

Timing of MHT Initiation

Evidence suggests that the effects of MHT on the progression of atherosclerosis and CVD events vary by age or time since menopause when MHT is initiated. Specifically, beneficial effects on CVD outcomes and all-cause mortality may occur when MHT is initiated

in women <60 years of age or <10 years since menopause, whereas null or harmful effects may occur when MHT is initiated at older ages or after greater time since menopause. Numerous observational studies before 1991, reflecting the clinical practice of initiation MHT use near the time of menopause, reported reduced rates of CHD in MHT users.¹⁵⁹ A 1991 analysis of prospective observational studies reported an overall summary relative risk of CHD events of 0.50 (95% CI, 0.43–0.56).¹⁶⁰ Analyses from the Nurses' Health Study (in women 30–55 years of age at baseline) showed a lower risk of mortality among current users compared with those who never used MHT (RR, 0.63 [95% CI, 0.56–0.70]), with the mortality reduction greater in women at higher risk.¹⁶¹ Case-control and cross-sectional studies also found reduced CHD morbidity with MHT for women with angiographically defined CHD.^{159,162–164}

Building on the above data, clinical trials of secondary prevention for CHD (HERS [Heart and Estrogen/Progestin Replacement Study]) and stroke (Women's Estrogen for Stroke Trial) were conducted in the 1990s with average ages at baseline of 67 and 72 years, respectively. Neither of these trials found benefit with MHT.^{165,166} Moreover, the WHI trials shared the premise that, because MHT appeared protective against CVD in observational studies that included recently menopausal women,¹⁶⁷ it might be more effective in women at greater risk. The WHI trial of conjugated equine estrogens (CEE) plus medroxy-progesterone acetate (MPA) found no CHD protection in the cohort overall (mean age, 63 years; 12 years postmenopausal; HR, 1.24 [95% CI, 1.00–1.57]).¹⁶⁸ However, trends were consistent with prior literature,^{155,160} with HRs of 0.89 in women within 10 years of menopause and 0.95 in women 50 to 59 years of age with hot flashes. Notably, these results were not statistically significant in the limited sample in these age ranges (31% of the cohort) because the WHI was heavily weighted toward women distant from menopause.¹⁶⁸

The WHI trial of CEEs alone in women with hysterectomy also reported no benefit for CHD in the overall cohort 50 to 79 years of age (HR, 0.95 [95% CI, 0.79–1.16]). In this arm, women 50 to 59 years of age had a reduced risk of a composite coronary outcome [HR, 0.66 [95% CI, 0.45–0.96]] but not of the primary outcome (myocardial infarction or coronary death), probably because of the low event rate in young women.¹⁶⁹ HRs for stroke were elevated by 35% to 40% with both MHT regimens in the overall WHI cohorts of women 50 to 79 years of age, without significant interaction by age. However, in women 50 to 59 years of age, stroke event rates were identical with CEE and placebo.^{170,171}

In an overview of findings from the intervention and extended postintervention phases of the 2 WHI trials, results for CHD and stroke were similar to those of earlier reports.¹⁷² Consistent with observational studies,

all-cause mortality was reduced 31% relative to placebo in women 50 to 59 years of age only when the 2 MHT trials were pooled (because of their similar results for mortality). The test for trend by age was significant ($P=0.01$), indicating a contrast in mortality between younger and older women.¹⁷³ DOPS (Danish Osteoporosis Prevention Study) tested oral estradiol alone in women with hysterectomy and combined with norethisterone acetate in women with an intact uterus. Mean age was 50 years, and the primary end point was a composite of hospitalized heart failure, myocardial infarction, and death. After 10 years of treatment, the primary end point was reduced with MHT (HR, 0.48 [95% CI, 0.26–0.87]), and the effect on stroke was null.¹⁷⁴

A meta-analysis of randomized trials in young postmenopausal women (mean age, 55 years) suggested a 27% reduction (RR, 0.73 [95% CI, 0.52–0.96]) in mortality with MHT compared with no treatment.¹⁷⁵ Similarly, meta-analyses limited to trial data stratified by either age or time since menopause showed that MHT may decrease CHD and all-cause mortality by 30% to 48% when initiated in women <60 years of age or <10 years since menopause.^{176–179} In the most recent Cochrane systematic review evaluating RCTs of MHT for preventing CHD in postmenopausal women, among women initiating MHT at <60 years of age or <10 years since menopause, CHD risk was reduced by roughly half (RR, 0.52 [95% CI, 0.29–0.96]) and all-cause mortality by 30% (RR, 0.70 [95% CI, 0.52–0.95]). Venous thromboembolism was increased (RR, 1.74 [95% CI, 1.11–2.73]), but there was no evidence of an excess risk of stroke with MHT.¹⁷⁸ In contrast, in women initiating MHT at >60 years of age or >10 years since menopause, MHT had no effect on CHD or all-cause mortality.¹⁷⁸ Of note, risks for stroke and venous thromboembolism were increased.¹⁷⁸

The timing effect was also examined with the use of nationwide registers of postmenopausal MHT use ($n=498\,105$) in Finland (1994–2009) to evaluate CHD death among users of estradiol-based MHT according to age at the initiation of therapy.¹⁸⁰ The CHD standardized mortality ratio was lower among women who initiated MHT at <60 years of age compared with those initiating at older ages (for estradiol alone, 0.53 [95% CI, 0.47–0.59] versus 0.76 [95% CI, 0.71–0.82]; for estradiol/progestin, 0.45 [95% CI, 0.41–0.49] versus 0.74 [95% CI, 0.67–0.81]).¹⁸⁰

Two trials have assessed the effect of MHT on the age-related increase in cIMT, an established measurement of atherosclerosis progression.^{181–184} In the 4-year KEEPS trial, low-dose oral (CEE 0.45 mg/d) and patch (estradiol 50 μ g/d) estrogen had no significant effect on cIMT progression in healthy newly menopausal women.¹⁸⁵ In contrast, the 5-year ELITE trial (Early Versus Late Intervention Trial With Estradiol) showed reduced cIMT

progression with oral estradiol 1 mg daily in women <6 years, but not in women >10 years, postmenopausal (P for interaction=0.007).¹⁸⁶ The reasons for the outcome differences between KEEPS and ELITE are unclear, but a possibility is a higher dose of estrogen in the latter.¹⁸⁷

Route of Administration and MHT Formulations

Clinical trial comparisons of MHT formulations and routes of administration with CVD outcomes are not available. Recent evidence from large observational studies suggests potential differential effects based on the type of estrogen, route of administration, or type of progestin agent in combined regimens. A report from the WHI observational study of 93 676 postmenopausal women (50–79 years of age at baseline) followed up between 1994 and 2009 compared CVD outcomes among various estrogen regimens. Nonsignificant trends for lower rates of CHD, stroke, and CVD mortality, but not all-cause mortality, were reported for transdermal estradiol compared with oral CEEs.¹⁸⁸ In a US matched-cohort study of health insurance claims between 1999 and 2011, transdermal estrogen preparations were associated with a lower incidence of CVD complications compared with oral estrogen preparations (incidence rate ratio, 0.81 [95% CI, 0.67–0.99]), regardless of the type of estrogen agent used.¹⁸⁹ Most recently, 2 large nested case-control studies using the QResearch and Clinical Practice Research Datalink database in the United Kingdom evaluated the associations between various MHT regimens and the risk of venous thromboembolism.¹⁹⁰ Oral MHT preparations were associated with increased venous thromboembolism, whereas transdermal preparations were not. CEE was associated with a higher risk than estradiol. Within the oral regimens, CEE+MPA had the highest risk, and estradiol+dydrogesterone had the lowest. Micronized progesterone was not evaluated.¹⁹⁰

MHT Use as Related to Cardiometabolic and Vascular Health

Body Fat Distribution

After 3 years of treatment, lean soft tissue mass was preserved and upper body fat distribution, assessed as change in ratio of trunk to leg fat mass, was lower among WHI women in the CEE+MPA group compared with those in the placebo group.¹⁹¹ In PEPI (Postmenopausal Estrogen/Progestin Interventions Study), women on CEE-based regimens averaged 1 kg less weight gain ($P=0.006$) and 1.2 cm less increase in waist circumference ($P=0.01$) than those given placebo after 3 years of follow-up.¹⁹² In KEEPS, although no statistically significant differences were observed in BMI changes across

treatment groups, women on oral CEE showed smaller increases in BMI compared with those on transdermal estradiol or placebo. There was also a trend for less increase in waist circumference.¹⁹³

Metabolic Syndrome Components

In PEPI, CEE-based regimens were associated with decreases in fasting glucose ($P=0.03$) and fasting insulin ($P=0.07$), but there was no effect on SBP or DBP.¹⁹⁴ In KEEPS, transdermal estradiol was associated with decreases in fasting insulin and fasting glucose versus placebo, whereas oral CEE was not. However, both oral and transdermal treatments were associated with significant decreases in insulin resistance, measured via the Homeostatic Model Assessment of Insulin Resistance score, compared with placebo.¹⁸⁵ In both the WHI and HERS, CEE+MPA was associated with a reduced incidence of type 2 diabetes, as was CEE alone in the WHI.^{172,195}

Vascular Health

ELITE showed lower cIMT progression with oral estradiol versus placebo in women <6 years postmenopausal.¹⁸⁶ However, at a lower dose of oral CEE or transdermal estradiol versus placebo, KEEPS showed no benefit in cIMT progression and no change in coronary artery calcium score in women <3 years postmenopausal.¹⁸⁵ Among WHI women 50 to 59 years of age, CEE alone was associated with lower mean coronary artery calcium score assessed ≈ 1 year after trial completion ($P=0.02$), and differences were larger in women at least 80% adherent to study treatment.¹⁹⁶

Stopping MHT

To assess related risks of cardiovascular events and all-cause mortality after MHT is stopped, surviving participants from both WHI trials (CEE+MPA trial and CEE alone trial) were followed up after trial completion for a median of 8.2 years in the CEE+MPA trial and 6.6 years in the CEE alone trial. In both cases, postintervention results were neutral for CHD, stroke, pulmonary embolism, and all-cause mortality.¹⁷² Conversely, a Finnish national study of 1.97 million women-years of follow-up (baseline age, 40–107 years) reported a >2-fold increase in cardiac and stroke deaths in the first year after stopping MHT use (median age at starting, 52 years; median age at stopping, 59 years).¹⁹⁷ Results were the same in a follow-up analysis that excluded women with nonfatal cardiac or stroke events within 1 year before stopping MHT.¹⁹⁸ Notably, the risks were greater in Finnish women <60 years of age or in those who used MHT for >5 years.^{197,198} However, results from the randomized WHI trials and the observational Finnish studies are likely not comparable because of differences in study designs, characteristics of study populations, and the MHT regimens. The Finnish study did not

have any data on the reasons why MHT was stopped or the cardiovascular risk factors during MHT use that may have led to stopping MHT.

In summary, positive early expectations for MHT on the prevention of CVD were based on data derived mostly from observational studies and 1 clinical trial (which focused on CVD risk factors) of newly menopausal women. Later, these were replaced by a concern for harm in trials that enrolled women who were on average a decade or more postmenopausal. Since then, evolving research has shown that timing of initiation is likely relevant to coronary benefit and that there may be differences by route of administration and treatment regimen. Current recommendations from leading specialty societies endorse the use of MHT in recently menopausal women with appropriate indications.^{199–201} The evidence supports cardiovascular benefit for MHT initiated early among women with premature or surgical menopause and within 10 years of menopause in women with natural menopause. The benefits of MHT (ie, including lower rates of diabetes, reduced insulin resistance, and protection from bone loss) appear to outweigh risks for the majority of early menopausal women. Perimenopausal women should be provided individualized guidance on MHT and options for treatment, particularly when vasomotor symptoms are present.

LIPID-LOWERING MEDICATIONS IN WOMEN

Although an optimal lipid profile is a measurable objective in the prescription of lipid-lowering therapies for women with elevated risk, data for primary and secondary prevention of atherosclerotic CVD and improved survival with lipid-lowering interventions remain elusive for women. Nonpharmacological therapies that incorporate lifestyle modification (exercise, weight loss, smoking cessation, and heart-healthy diet) are recommended as the first-line strategy for improving lipid profiles.²⁰² In addition, dietary interventions, herbal products, and nutritional supplements have been used in holistic practices to promote health and to prevent the development of heart disease.²⁰³ ω -3 and ω -6 polyunsaturated fatty acids have been evaluated extensively in this regard. For example, in a recent meta-analysis, ω -3 was significantly associated with reductions in CHD (RR, 0.93 [95% CI, 0.89–0.98]) and myocardial infarction (RR, 0.92 [95% CI, 0.85–0.99]) but not CVD mortality (RR, 0.98 [95% CI, 0.93–1.02]) or all-cause mortality (RR, 0.93 [95% CI, 0.86–1.01]).²⁰³ Similarly, in a Cochrane analysis, ω -6 acids were found to lower total cholesterol (mean difference, -0.33 mmol/L [95% CI, -0.50 to -0.16]), but the reduction of myocardial infarction in high-risk individuals was

not statistically significant (RR, 0.88 [95% CI, 0.76–1.02]).²⁰⁴ Notably, the ω -3 and -6 studies included relatively few women, for whom menopausal status was unreported, challenging a general application of these results to this population.

Numerous studies have evaluated lipid-lowering medications for the prevention of atherosclerotic CVD, with most focusing on HMG-CoA reductase inhibitors (ie, statins). Limited RCT evidence for the primary prevention of CVD with statin therapy derives from a cohort of women (n=6801) with baseline LDL-C <130 mg/dL and high-sensitivity C-reactive protein >2 mg/dL studied in the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).²⁰⁵ Although fatal and nonfatal myocardial infarction and all-cause mortality were not reduced with statin therapy across the entire cohort of women in JUPITER, arterial revascularization was reduced in the subgroup of women >60 years of age.²⁰⁵

In the MEGA trial (Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese), in which a large cohort of women (n=5356) were followed up for >5 years of statin therapy, the effect on CHD and all-cause mortality was null.²⁰⁶ In a subgroup analysis, noncardiovascular mortality was reduced in women >55 years of age.²⁰⁶ Furthermore, the sex-specific data from the online supplement of the HOPE-3 trial (Heart Outcomes Prevention Evaluation-3), a large RCT of women (n=5871) and men (n=6831) with intermediate risk for CHD, provide further evidence that statin therapy had a nonsignificant effect on CHD and all-cause mortality for primary prevention in women.²⁰⁷

Of the meta-analyses comparing primary prevention trials of statin therapy, primary prevention of CHD has been demonstrated in men (n=28 346; RR, 0.59 [95% CI, 0.48–0.74]²⁰⁸; and n=26 921; RR, 0.72 [95% CI, 0.61–0.86]²⁰⁹) but not in women (n=13 346; RR, 0.89 [95% CI, 0.79–1.00]²⁰⁸; and n=20 817; RR, 0.79 [95% CI, 0.56–1.13]²⁰⁹), whereas the results for all-cause mortality were null for both sexes.^{208,209} In a large meta-analysis of primary and secondary prevention trials of the Cholesterol Treatment Trialists' database comprising 46 675 (27%) women, the effect size of primary prevention with statin therapy was smaller and nonsignificant in women compared with men (rate ratio of major vascular event, 0.72 [95% CI, 0.66–0.80] in men versus 0.85 [95% CI, 0.72–1.00] in women).²¹⁰ Simultaneous incorporation of both primary and secondary prevention trials into the analysis strengthened the finding of a CVD reduction in women. A meta-analysis that analyzed primary and secondary prevention trials with statin therapy separately in women showed a significant reduction in CHD events in secondary (n=6,185; RR, 0.80 [95% CI, 0.71–0.91]), but not in primary, prevention (n=9806; RR, 0.87 [95% CI, 0.69–1.09]). All-cause mortality in women was not reduced

by statin therapy in primary (n= 7677; RR, 0.95 [95% CI, 0.62–1.46]) or secondary prevention (n=2393; RR, 1.00 [95% CI, 0.77–1.29]).²¹¹

Although statin therapy is first-line therapy to lower LDL-C, other treatments may be considered as adjuncts or alternatives to improve the lipid profile resulting from inadequate LDL-C control or statin intolerance. The most common nonstatin therapies are bile acid sequestrants, cholesterol absorption inhibitors (ezetimibe), and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. The relative safety and efficacy of ezetimibe have been shown in women and men.²¹² The options for lipid-lowering therapies are evolving rapidly. PCSK9 inhibitors and other targeted therapies hold unique promise in the future of CVD risk reduction therapies, but clinical trials are needed to disaggregate sex differences for women versus men. Observational data suggest that serum PCSK9 levels are higher in postmenopausal women, but the clinical significance of this finding is unknown.^{213–215} Available data suggest no sex-based difference in low-density lipoprotein reduction for the newly US Food and Drug Administration–approved ATP citrate lyase inhibitor bempedoic acid.²¹⁶ On the basis of the limitations in the effectiveness of statins in improving hard outcomes for women, the new lipid-lowering medications (PCSK9 inhibitors, bempedoic acid, siRNA [small interfering RNA] class of agents [eg, inclisiran], MTTP [microsomal triglyceride transfer protein] inhibitors [eg, lomitapide], antisense oligonucleotides, and others) warrant sex-specific trials to determine efficacy for hard end points. Although evidence-based data supporting a statistically significant reduction of CVD events and all-cause mortality in primary prevention in women are lacking for statins and other lipid-lowering therapies, the current guidelines for the prevention of CVD do not provide specific recommendations for women and men independently. Therefore, the most recent lipid-lowering guidelines recommend statins as first-line therapy for CVD risk reduction, regardless of sex or menopausal status.

LATEST AHA GUIDELINES ON CVD PREVENTION IN WOMEN

Summary of Guidelines

On the basis of a review of the literature on unique aspects of CVD in women, the AHA published scientific statements addressing prevention of CVD in women in 1997 and 1999.^{217,218} Using clinical criteria or the Framingham global risk score,²¹⁹ an expert panel updated the 1999 statement in 2004 to develop the first AHA evidence-based guidelines for CVD prevention in women, emphasizing the spectrum of CVD and classifying women as being at high risk, intermediate risk, low risk, and optimal risk.²²⁰ In 2007, a further update of these

guidelines recommended a general approach to classify women as high risk, at risk, or optimal risk,²²¹ recognizing that the average lifetime risk for CVD was nearly 1 in 2 in women.²²² This scheme aligned the guidelines well with available clinical trial evidence, most of which was for women at high risk or apparently healthy women with a spectrum of risk.²²¹ The 2007 panel also acknowledged the growing appreciation of the limitations of risk stratification with the Framingham risk function in diverse populations of women.²²³

In 2011, another AHA panel updated the 2007 recommendations as effectiveness-based guidelines for the prevention of CVD in women, which considered benefits and risks of preventive therapies observed in clinical practice rather than limiting recommendations to evidence that documented efficacy.⁶ The 2011 panel continued to emphasize categorical classification of CVD risk in women as high risk, at risk, and ideal cardiovascular health, which replaced the former optimal risk category. Ideal cardiovascular health was defined by the absence of clinical CVD and the presence of all ideal levels of total cholesterol (<200 mg/dL), blood pressure (<120/80 mm Hg), and fasting blood glucose (<100 mg/dL), as well as adherence to healthy behaviors, including having a BMI <25 kg/m²; abstaining from smoking; engaging in moderate- or vigorous-intensity physical activity at ≥150 or ≥75 min/wk, respectively, or a combination; and following a healthy (DASH-like) diet.¹²¹

Although these national goals were not specific to women, available data on women were evaluated in their development,¹²¹ and on the basis of these findings, the 2011 expert panel stated that “when achieved or maintained into middle age, the overall pattern of ideal cardiovascular health is associated with greater longevity” and “dramatic reductions in short-term, intermediate-term, and lifetime risks for CVD events.”⁶ Other notable modifications to the risk classification algorithm included acknowledging the availability of several risk equations for the prediction of 10-year global CVD risk such as the updated Framingham CVD risk profile and the Reynolds risk score for women^{224,225} and adding factors to the at-risk status group that are known to be more prevalent among women and possibly making special contributions to CVD risk in women. Specifically, systemic autoimmune collagen-vascular disease (eg, systemic lupus erythematosus or rheumatoid arthritis) and history of preeclampsia, gestational diabetes, or pregnancy-induced hypertension were included (Table).⁶ Notably, menopause and menarche were mentioned only as periods of potential vulnerability across women's life span, which should be evaluated by future research to identify women at risk and to determine the effectiveness of diagnostic and preventive interventions during these critical times.⁶

The 2011 guidelines retained the Class III recommendations from the 2007 guidelines²²¹ that MHT,

Table. Classification of CVD Risk in Women

Risk Status	Criteria
High risk (≥1 high-risk states)	Clinically manifest CHD
	Clinically manifest cerebrovascular disease
	Clinically manifest peripheral arterial disease
	Abdominal aortic aneurysm
	End-stage or chronic kidney disease
	Diabetes
	10-y Predicted CVD risk ≥10%
At risk (≥1 major risk factors)	Cigarette smoking
	SBP ≥120 mm Hg, DBP ≥80 mm Hg, or treated hypertension
	Total cholesterol ≥200 mg/dL, HDL-C <50 mg/dL, or treated for dyslipidemia
	Obesity, particularly central adiposity
	Poor diet
	Physical inactivity
	Family history of premature CVD occurring in first-degree relatives in men <55 y of age or in women <65 y of age
	Metabolic syndrome
	Evidence of advanced subclinical atherosclerosis (eg, coronary calcification, carotid plaque, or thickened IMT)
	Poor exercise capacity on treadmill test or abnormal heart rate recovery after stopping exercise
	Systemic autoimmune collagen-vascular disease (eg, lupus or rheumatoid arthritis)
	History of preeclampsia, gestational diabetes, or pregnancy-induced hypertension
Ideal cardiovascular health (all of these)	Total cholesterol <200 mg/dL (untreated)
	BP <120/<80 mm Hg (untreated)
	Fasting blood glucose <100 mg/dL (untreated)
	BMI <25 kg/m ²
	Abstinence from smoking
	Physical activity at goal for adults >20 y of age: ≥150 min/wk moderate intensity, ≥75 min/wk vigorous intensity, or combination
	Healthy (DASH-like) diet

BMI indicates body mass index; BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; HDL-C; high-density lipoprotein cholesterol; IMT, intima-media thickness; and SBP, systolic blood pressure.

Reprinted from Mosca et al.⁶ Copyright © 2011, American Heart Association, Inc.

selective estrogen-receptor modulators, antioxidant vitamin supplements (eg, vitamin E, vitamin C, and β-carotene), and folic acid (with or without vitamin B₆ and B₁₂ supplementation) should not be used for primary or secondary prevention of CVD. The guidelines also stated that routine use of aspirin in healthy women <65 years of age is not recommended to prevent myocardial infarction.⁶

The AHA guidelines for the prevention of stroke in women published in 2014²²⁶ stated that no study had investigated the relationship between endogenous hormones and stroke as women transition through menopause. The authors referenced a review on the role of menopause and MHT in stroke risk, which is lower in women than men during middle age but doubles during the 10 years after menopause,²²⁷ and a review of observational studies of the association of premature (before 40 years of age) or early (between 40 and 45 years of age) menopause and the risk of ischemic stroke.²²⁸ These observational cohort studies demonstrated an increased risk of all types of stroke in women who underwent BSO before 50 years of age compared with women who retained their ovaries.²²⁸ The AHA guidelines stated that neither postmenopausal MHT (specifically CEE with or without MPA) nor selective estrogen-receptor modulators should be used for the primary or secondary prevention of stroke in postmenopausal women.²²⁶

Sex-related differences in the cardiovascular system were outlined in a 2016 AHA scientific statement on preventing and experiencing ischemic heart disease as a woman,²²⁹ but the discussion of menopause was limited to statements on the changes in body fat discussed in previous sections of this scientific statement and results from a blood pressure study showing no differences by menopausal status in blood pressure in 152 hypertensive women (40–60 years of age) versus 40 age-matched normotensive control subjects.²³⁰ To date, the concurrence of advancing age and menopause with increasing blood pressure continues to raise doubt as to whether menopause is an independent risk factor for high BP,²³¹ a major risk factor for stroke.

Premature menopause has been recognized as a risk-enhancing factor favoring statin therapy initiation in the 2018 updated guidelines of blood cholesterol management.²⁰²

Implications of the Evolving Findings on Menopause and CVD Risk on These Guidelines

As presented in the Menopause Characteristics Relevant to CVD Risk section, an association between age at natural menopause and CVD risk has been observed in many, but not all, population cohorts, as has a higher CVD risk with surgical menopause with BSO, particularly in women <45 years of age. However, the 2011 classification of CVD risk in women does not include early menopause among categorical risk factors. As also presented in previous sections of this statement, adverse changes in lipids and body fat deposition and increases in metabolic syndrome risk have been related to the MT independently of aging. However, the most recent AHA guidelines for CVD prevention in women have not fully

addressed menopause and its related cardiometabolic consequences as independent risk factors,⁶ nor have more recent AHA statements on stroke in women.²²⁶

The North American Menopause Society published key points and recommendations for the clinical care of midlife women in 2014, including that all women be evaluated for CVD risk with the American College of Cardiology/AHA risk assessment tool and these risks managed accordingly.²³² Future risk assessment guidelines should include menopause among CVD risk factors in women. Until the next consensus guidelines are presented, we believe the North American Menopause Society recommendation should be promoted.

SUMMARY AND CONCLUSIONS

Menopause signifies the permanent cessation of ovarian reproductive function. The transition from any level of function, manifested by uterine menstruation, to the absence of menses is referred to as the MT and is characterized as the time when the menstrual cycles become significantly variable or other menopause-related symptoms begin. The MT is a period of significant symptomatic, hormonal, menstrual, and other physiological changes that are relevant to CVD risk. Accordingly, the purpose of this scientific statement was to provide a contemporary synthesis of the existing data on the MT and how these data relate to CVD, the leading cause of mortality in US women. Here, we summarize the salient content provided in the preceding sections:

1. The median age of natural menopause is 50 years. Natural menopause is considered premature if it occurs before 40 years of age and early if it occurs between 40 and 45 years of age.
2. Because of the trends for increases in overall life expectancy in the United States, a significant proportion of women will spend up to 40% of their lives postmenopausal.
3. Earlier age at natural menopause is generally reported as a marker of greater CVD risk and linked to being Black or Hispanic, having a short menstrual cycle length, having a low parity, being a smoker, and having a worse cardiovascular health profile during reproductive life. Of note, the studies on age of natural menopause and incident morbidity and mortality are not entirely consistent, which may be the result of different formulations of the composite outcomes.
4. Iatrogenically induced menopause (ie, BSO) during the premenopausal period is associated with higher CVD risk. Hysterectomy, regardless of ovarian status, does not influence CVD risk factors before or after menopause. Guidelines from the North American Menopause Society endorse MHT use among women with premature or early natural or surgical menopause, with treatment

until at least the median age of menopause (in the absence of contraindications).

5. Vasomotor symptoms are associated with worse CVD risk factor levels and measures of subclinical atherosclerosis. These associations may depend on the timing of these symptoms during the MT.
6. Sleep disturbance, a common complaint during the MT, is linked to a greater risk of subclinical CVD and worse cardiovascular health indexes in midlife women.
7. Depression occurs more frequently during the perimenopausal and postmenopausal years and is related to both vasomotor symptoms and incident CVD.
8. The perimenopause stage begins with the onset of intermenstrual cycle irregularities or other menopause-related symptoms. This stage extends 12 months after menopause and has been identified as a stage of vulnerability accompanied by significant alterations in several cardiometabolic and vascular health parameters strongly linked to higher CVD risk.
9. Central/visceral fat increases and lean muscle mass decreases are more pronounced during the MT. The increased central adiposity is associated with an increased risk of mortality, even among those with normal BMI.
10. Paracardial fat volumes are higher after menopause, independently of age, and could be influenced by estradiol levels or MHT use.
11. Increases in lipids (LDL-C and apolipoprotein B), metabolic syndrome risk, and vascular remodeling at midlife are driven by the MT more than aging, whereas increases in blood pressure, insulin, and glucose are likely more influenced by chronological aging.
12. Novel data show a reversal in the associations of HDL-C with CVD risk over the MT, suggesting that higher HDL-C levels may not consistently reflect good cardiovascular health in midlife women.
13. Limited data exist on the current status of ideal cardiovascular health components in women during the MT. According to this limited literature, only 7.2% of women traversing menopause report a physical activity level that matches the current recommendation, and <20% consistently maintain a healthy eating diet.
14. Although the data are limited, randomized trial results suggest that a multidimensional lifestyle intervention can prevent weight gain while reducing triglycerides, SBP, and DBP, as well as blood glucose, insulin, and subclinical carotid atherosclerosis, among women undergoing the MT.
15. Regardless of the strong line of observational evidence showing the MT as a period of accelerated

cardiovascular risk, RCTs of lifestyle and behavioral interventions have not adequately represented this high-risk population.

16. The literature supporting a critical role for the time of initiation of MHT use relative to menopause, with initiation at <60 years of age or within 10 years of menopause appearing to be associated with reduced CVD risk, strongly calls for further research assessing MHT use, including potential contrasts by form, route, and duration of administration, on cardiometabolic effects in women traversing menopause, a large proportion of whom experience menopausal symptoms before even reaching menopause.
17. Data for primary and secondary prevention of atherosclerotic CVD and improved survival with lipid-lowering interventions remain elusive for women, with further study required for evidence-based recommendations to be developed specifically for women.

As is evident from the information provided in this statement, the MT is a uniquely impactful period of time in most women's lives, which is associated with adverse changes in CVD risk. Trial results suggest that behavioral interventions can be used effectively during this time frame to reduce adverse CVD profiles. However, the number of randomized trials and observational studies including women during this transition is remarkably constrained. Therefore, definitive conclusions from the data are difficult to make with reasonable certainty. Unfortunately, this has left a substantial proportion of women and their healthcare providers unsure about how to proceed with interventions such as lipid-lowering medications and MHT use. Because the MT is a period of significant detrimental changes in several cardiometabolic risk factors (ie, lipids, vascular health, metabolic syndrome, visceral adiposity), healthcare practitioners may consider an aggressive prevention-based approach for women at this stage in their lives to decrease the probability of a future CVD event. On the basis of the data collected to date, a reasonable lifestyle intervention would target ideal body weight with low central adiposity and maintenance of skeletal muscle mass.

To further assist these practitioners and to reduce the burden of CVD while improving quality of life in this population of women, it is strongly recommended that future studies make a conscious effort to include or to focus on women who are undergoing the MT, especially those related to MHT and other therapeutic interventions. Studies that do so should carefully consider how to integrate women's reproductive aging into the study design vis-à-vis surveys, case report forms, etc. In addition, new studies may ponder the inclusion of more contemporary or emerging biomarkers of reproductive aging such as the anti-Müllerian hormone, which has

been linked to the MT and the timing of menopause²³³ and may complement information obtained from the more traditional hormone measures.

ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on May 22, 2020, and the American Heart Association Executive Committee on June 22, 2020. A copy of the document is available at <https://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 215-356-2721 or email Meredith.Edelman@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, Limacher MC, Manson JE, Stefanick ML, Allison MA; on behalf of the American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. *Circulation*. 2020;142:e506–e532. doi: 10.1161/CIR.0000000000000912

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Samar R. El Khoudary	University of Pittsburgh	None	None	None	None	None	None	None
Matthew A. Allison	University of California, San Diego	None	None	None	None	None	None	None
Brooke Aggarwal	Columbia University Irving Medical Center	American Heart Association (PI)†	None	None	None	None	None	None
Theresa M. Beckie	University of South Florida	None	None	None	None	None	None	None
Howard N. Hodis	University of Southern California Keck School of Medicine	None	None	None	None	None	None	None
Amber E. Johnson	University of Pittsburgh–UPMC Heart and Vascular Institute	None	None	None	None	None	None	Veterans' Health Administration (staff cardiologist)†
Robert D. Langer	Jackson Hole Center for Preventive Medicine	None	None	Pfizer India†	None	None	None	None
Marian C. Limacher	University of Florida College of Medicine	NIH (Women's Health Initiative)*	None	None	None	None	None	None
JoAnn E. Manson	Brigham and Women's Hospital, Harvard Medical School	None	None	None	None	None	None	None
Marcia L. Stefanick	Stanford University Prevention Research Center	None	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns \$10000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Jo-Ann Eastwood	UCLA	None	None	None	None	None	None	None
Edward R. O'Brien	University of Calgary (Canada)	CIHR (Sex & Gender Science Chair Grant and Women's Health Clinical Mentorship Grant under review)*	None	None	None	Pemi31, Inc Therapeutics (cofounder and chief scientific officer)*	None	None
Lily L. Yanes Cardozo	University of Mississippi	None	None	None	None	None	None	None
Markella V. Zanni	Massachusetts General Hospital, Harvard Medical School	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

REFERENCES

- Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association [published correction appears in *Circulation*. 2020;141:e33]. *Circulation*. 2019;139:e56–e58. doi: 10.1161/CIR.0000000000000659
- Mosca L, Hammond G, Mochari-Greenberger H, Towfighi A, Albert MA; on behalf of the American Heart Association Cardiovascular Disease and Stroke in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on High Blood Pressure Research, and Council on Nutrition, Physical Activity and Metabolism. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. *Circulation*. 2013;127:1254–1263, e1. doi: 10.1161/CIR.0b013e318287cf2f
- Bairey Merz CN, Andersen H, Sprague E, Burns A, Keida M, Walsh MN, Greenberger P, Campbell S, Pollin I, McCullough C, et al. Knowledge, attitudes, and beliefs regarding cardiovascular disease in women: the Women's Heart Alliance. *J Am Coll Cardiol*. 2017;70:123–132. doi: 10.1016/j.jacc.2017.05.024
- Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. *Ann Intern Med*. 1976;85:447–452. doi: 10.7326/0003-4819-85-4-447
- El Khoudary SR. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: a narrative review. *Maturitas*. 2017;104:44–53. doi: 10.1016/j.maturitas.2017.08.003
- Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association [published corrections appear in *Circulation*. 2011;123:e624 and *Circulation*. 2011;124:e427]. *Circulation*. 2011;123:1243–1262. doi: 10.1161/CIR.0b013e31820faaf8
- WHO Scientific Group on Research on the Menopause. Research on the menopause in the 1990s: report of a WHO scientific group. *World Health Organ Technical Report Series*. 1996;866:1–107.
- Zhu D, Chung HF, Pandeya N, Dobson AJ, Cade JE, Greenwood DC, Crawford SL, Avis NE, Gold EB, Mitchell ES, et al. Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: a pooled analysis of individual data from 17 observational studies. *PLoS Med*. 2018;15:e1002704. doi: 10.1371/journal.pmed.1002704
- Santoro N, El Khoudary SR, Sokalska A, Szmulowicz ED, Wolfman W. Menopause. In: *Menopause Practice: A Clinician's Guide*. Pepper Pike, OH: The North American Menopause Society; 2019:1–21.
- Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. *Natl Vital Stat Rep*. 2016;65:1–122.
- Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, Santoro N, Simoncini T. Menopause. *Nat Rev Dis Primers*. 2015;1:15004. doi: 10.1038/nrdp.2015.4
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. *J Clin Endocrinol Metab*. 2012;97:1159–1168. doi: 10.1210/jc.2011-3362
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; Straw + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. *Climacteric*. 2012;15:105–114. doi: 10.3109/13697137.2011.650656
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; Straw + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. *Fertil Steril*. 2012;97:843–851. doi: 10.1016/j.fertnstert.2012.01.128
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; Straw + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. *Menopause*. 2012;19:387–395. doi: 10.1097/gme.0b013e31824d8f40
- El Khoudary SR, Thurston RC. Cardiovascular implications of the menopause transition: endogenous sex hormones and vasomotor symptoms. *Obstet Gynecol Clin North Am*. 2018;45:641–661. doi: 10.1016/j.ogc.2018.07.006
- Tepper PG, Randolph JF Jr, McConnell DS, Crawford SL, El Khoudary SR, Joffe H, Gold EB, Zheng H, Bromberger JT, Sutton-Tyrrell K. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health across the Nation (SWAN). *J Clin Endocrinol Metab*. 2012;97:2872–2880. doi: 10.1210/jc.2012-1422
- Avis NE, Crawford SL, Green R. Vasomotor symptoms across the menopause transition: differences among women. *Obstet Gynecol Clin North Am*. 2018;45:629–640. doi: 10.1016/j.ogc.2018.07.005
- El Khoudary SR, Greendale G, Crawford SL, Avis NE, Brooks MM, Thurston RC, Karvonen-Gutierrez C, Waetjen LE, Matthews K. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). *Menopause*. 2019;26:1213–1227. doi: 10.1097/GME.0000000000001424
- Kravitz HM, Kazlauskaitė R, Joffe H. Sleep, health, and metabolism in midlife women and menopause: food for thought. *Obstet Gynecol Clin North Am*. 2018;45:679–694. doi: 10.1016/j.ogc.2018.07.008
- Mirer AG, Young T, Palta M, Benca RM, Rasmuson A, Peppard PE. Sleep-disordered breathing and the menopausal transition among participants

- in the Sleep in Midlife Women Study. *Menopause*. 2017;24:157–162. doi: 10.1097/GME.0000000000000744
18. Kravitz HM, Janssen I, Bromberger JT, Matthews KA, Hall MH, Ruppert K, Joffe H. Sleep trajectories before and after the final menstrual period in the Study of Women's Health Across the Nation (SWAN). *Curr Sleep Med Rep*. 2017;3:235–250. doi: 10.1007/s40675-017-0084-1
 19. Bromberger JT, Epperson CN. Depression during and after the perimenopause: impact of hormones, genetics, and environmental determinants of disease. *Obstet Gynecol Clin North Am*. 2018;45:663–678. doi: 10.1016/j.ogc.2018.07.007
 20. Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, van der Schouw YT. Age at menopause, cause-specific mortality and total life expectancy. *Epidemiology*. 2005;16:556–562. doi: 10.1097/01.ede.0000165392.35273.d4
 21. Kritz-Silverstein D, Barrett-Connor E. Early menopause, number of reproductive years, and bone mineral density in postmenopausal women. *Am J Public Health*. 1993;83:983–988. doi: 10.2105/ajph.83.7.983
 22. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. *Osteoporos Int*. 2003;14:525–530. doi: 10.1007/s00198-003-1408-1
 23. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, Kavousi M, Franco OH. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. *JAMA Cardiol*. 2016;1:767–776. doi: 10.1001/jamacardio.2016.2415
 24. Joakimsen O, Bønaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: the Tromsø Study. *J Clin Epidemiol*. 2000;53:525–530. doi: 10.1016/s0895-4356(99)00197-3
 25. Monnikhof EM, van der Schouw YT, Peeters PH. Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. *Breast Cancer Res Treat*. 1999;55:285–291. doi: 10.1023/a:1006277207963
 26. Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A, Trichopoulos D. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer, III: oral contraceptive use. *Int J Cancer*. 1991;49:61–65. doi: 10.1002/ijc.2910490112
 27. Gold EB. The timing of the age at which natural menopause occurs. *Obstet Gynecol Clin North Am*. 2011;38:425–440. doi: 10.1016/j.ogc.2011.05.002
 28. Henderson KD, Bernstein L, Henderson B, Kolonel L, Pike MC. Predictors of the timing of natural menopause in the Multiethnic Cohort Study. *Am J Epidemiol*. 2008;167:1287–1294. doi: 10.1093/aje/kwn046
 29. Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, Skurnick J. Factors associated with age at natural menopause in a multiethnic sample of midlife women. *Am J Epidemiol*. 2001;153:865–874. doi: 10.1093/aje/k153.9.865
 30. Bromberger JT, Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prospective study of the determinants of age at menopause. *Am J Epidemiol*. 1997;145:124–133. doi: 10.1093/oxfordjournals.aje.a009083
 31. Gold EB, Crawford SL, Avis NE, Crandall CJ, Matthews KA, Waetjen LE, Lee JS, Thurston R, Vuga M, Harlow SD. Factors related to age at natural menopause: longitudinal analyses from SWAN. *Am J Epidemiol*. 2013;178:70–83. doi: 10.1093/aje/kws421
 32. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. *Int J Fertil*. 1967;12(pt 2):77–126.
 33. Dorjgochoo T, Kallianpur A, Gao YT, Cai H, Yang G, Li H, Zheng W, Shu XO. Dietary and lifestyle predictors of age at natural menopause and reproductive span in the Shanghai Women's Health Study. *Menopause*. 2008;15:924–933. doi: 10.1097/gme.0b013e3181786adc
 34. Yasui T, Hayashi K, Mizunuma H, Kubota T, Aso T, Matsumura Y, Lee JS, Suzuki S. Factors associated with premature ovarian failure, early menopause and earlier onset of menopause in Japanese women. *Maturitas*. 2012;72:249–255. doi: 10.1016/j.maturitas.2012.04.002
 35. Mishra GD, Pandeya N, Dobson AJ, Chung HF, Anderson D, Kuh D, Sandin S, Giles GG, Bruinsma F, Hayashi K, et al. Early menarche, nulliparity and the risk for premature and early natural menopause. *Hum Reprod*. 2017;32:679–686. doi: 10.1093/humrep/dew350
 36. Wang M, Gong WW, Hu RY, Wang H, Guo Y, Bian Z, Lv J, Chen ZM, Li LM, Yu M. Age at natural menopause and associated factors in adult women: findings from the China Kadoorie Biobank study in Zhejiang rural area. *PLoS One*. 2018;13:e0195658. doi: 10.1371/journal.pone.0195658
 37. Nagel G, Altenburg HP, Nieters A, Boffetta P, Linseisen J. Reproductive and dietary determinants of the age at menopause in EPIC-Heidelberg. *Maturitas*. 2005;52:337–347. doi: 10.1016/j.maturitas.2005.05.013
 38. Szegda KL, Whitcomb BW, Purdue-Smithe AC, Boutot ME, Manson JE, Hankinson SE, Rosner BA, Bertone-Johnson ER. Adult adiposity and risk of early menopause. *Hum Reprod*. 2017;32:2522–2531. doi: 10.1093/humrep/dex304
 39. Pokoradi AJ, Iversen L, Hannaford PC. Factors associated with age of onset and type of menopause in a cohort of UK women. *Am J Obstet Gynecol*. 2011;205:34.e1–34.e13. doi: 10.1016/j.ajog.2011.02.059
 40. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B, et al; PRACTICAL Consortium; kConFab Investigators; AOCs Investigators; Generation Scotland; EPIC-InterAct Consortium; LifeLines Cohort Study. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat Genet*. 2015;47:1294–1303. doi: 10.1038/ng.3412
 41. Sarnowski C, Kavousi M, Isaacs S, Demerath EW, Broer L, Muka T, Franco OH, Ikram MA, Uitterlinden A, Franceschini N, et al. Genetic variants associated with earlier age at menopause increase the risk of cardiovascular events in women. *Menopause*. 2018;25:451–457. doi: 10.1097/GME.0000000000001017
 42. Kok HS, van Asselt KM, van der Schouw YT, van der Tweel I, Peeters PH, Wilson PW, Pearson PL, Grobbee DE. Heart disease risk determines menopausal age rather than the reverse. *J Am Coll Cardiol*. 2006;47:1976–1983. doi: 10.1016/j.jacc.2005.12.066
 43. Zhu D, Chung HF, Pandeya N, Dobson AJ, Hardy R, Kuh D, Brunner EJ, Bruinsma F, Giles GG, Demakakos P, et al. Premenopausal cardiovascular disease and age at natural menopause: a pooled analysis of over 170,000 women. *Eur J Epidemiol*. 2019;34:235–246. doi: 10.1007/s10654-019-00490-w
 44. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. *Int J Epidemiol*. 2014;43:1542–1562. doi: 10.1093/ije/dyu094
 45. Torgerson DJ, Avenell A, Russell IT, Reid DM. Factors associated with onset of menopause in women aged 45–49. *Maturitas*. 1994;19:83–92. doi: 10.1016/0378-5122(94)90057-4
 46. Nagata C, Takatsuka N, Kawakami N, Shimizu H. Association of diet with the onset of menopause in Japanese women. *Am J Epidemiol*. 2000;152:863–867. doi: 10.1093/aje/k152.9.863
 47. Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. Association of diet and other lifestyle with onset of menopause in Japanese women. *Maturitas*. 1998;29:105–113. doi: 10.1016/s0378-5122(98)00012-7
 48. Taneri PE, Kiefte-de Jong JC, Bramer WM, Daan NM, Franco OH, Muka T. Association of alcohol consumption with the onset of natural menopause: a systematic review and meta-analysis. *Hum Reprod Update*. 2016;22:516–528. doi: 10.1093/humupd/dmw013
 49. Parente RC, Faerstein E, Celeste RK, Werneck GL. The relationship between smoking and age at the menopause: a systematic review. *Maturitas*. 2008;61:287–298. doi: 10.1016/j.maturitas.2008.09.021
 50. Voorhuis M, Onland-Moret NC, van der Schouw YT, Fauser BC, Broekmans FJ. Human studies on genetics of the age at natural menopause: a systematic review. *Human Reproduction*. 2010;16:364–377.
 51. He C, Kraft P, Chasman DI, Buring JE, Chen C, Hankinson SE, Paré G, Chanock S, Ridker PM, Hunter DJ. A large-scale candidate gene association study of age at menarche and age at natural menopause. *Hum Genet*. 2010;128:515–527. doi: 10.1007/s00439-010-0878-4
 52. Stolk L, Perry JR, Chasman DI, He C, Mangino M, Sulem P, Barbalic M, Broer L, Byrne EM, Ernst F, et al; LifeLines Cohort Study. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. *Nat Genet*. 2012;44:260–268. doi: 10.1038/ng.1051
 53. Perry JR, Hsu YH, Chasman DI, Johnson AD, Elks C, Albrecht E, Andrusis IL, Beesley J, Berenson GS, Bergmann S, et al; kConFab Investigators; ReproGen Consortium. DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. *Hum Mol Genet*. 2014;23:2490–2497. doi: 10.1093/hmg/ddt620
 54. Shi J, Zhang B, Choi JY, Gao YT, Li H, Lu W, Long J, Kang D, Xiang YB, Wen W, et al. Age at menarche and age at natural menopause in East Asian women: a genome-wide association study. *Age (Dordr)*. 2016;38:513–523.
 55. Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, Bandinelli S, Salfati E, Manson JE, Quach A, et al. Menopause accelerates

- biological aging. *Proc Natl Acad Sci USA*. 2016;113:9327–9332. doi: 10.1073/pnas.1604558113
56. Ley SH, Li Y, Tobias DK, Manson JE, Rosner B, Hu FB, Rexrode KM. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. *J Am Heart Association*. 2017;6:e006713. doi: 10.1161/JAHA.117.006713
 57. Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. *J Am Heart Assoc*. 2016;5:e003769. doi: 10.1161/JAHA.116.003769
 58. Simon T, Beau Yon de Jonage-Canonico M, Oger E, Wahl D, Conard J, Meyer G, Emmerich J, Barrellier MT, Guiraud A, Scarabin PY; ESTrogen and THromboEmbolic Risk (ESTHER) Study Group. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. *J Thromb Haemost*. 2006;4:71–76. doi: 10.1111/j.1538-7836.2005.01693.x
 59. Tom SE, Cooper R, Wallace RB, Guralnik JM. Type and timing of menopause and later life mortality among women in the Iowa Established Populations for the Epidemiological Study of the Elderly (EPESE) cohort. *J Womens Health (Larchmt)*. 2012;21:10–16. doi: 10.1089/jwh.2011.2745
 60. Dam V, van der Schouw YT, Onland-Moret NC, Groenwold RHH, Peters SAE, Burgess S, Wood AM, Chirlaque MD, Moons KGM, Oliver-Williams C, et al. Association of menopausal characteristics and risk of coronary heart disease: a pan-European case-cohort analysis. *Int J Epidemiol*. 2019;48:1275–1285. doi: 10.1093/ije/dyz016
 61. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. *N Engl J Med*. 1987;316:1105–1110. doi: 10.1056/NEJM198704303161801
 62. Lobo RA. Surgical menopause and cardiovascular risks. *Menopause*. 2007;14(pt 2):562–566. doi: 10.1097/gme.0b013e318038d333
 63. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses' Health Study. *Obstet Gynecol*. 2013;121:709–716. doi: 10.1097/AOG.0b013e3182864350
 64. Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, Januzzi JL Jr, Scott NS, Natarajan P. Association of premature natural and surgical menopause with incident cardiovascular disease [published online November 18, 2019]. *JAMA*. doi:10.1001/jama.2019.19191. <https://jamanetwork.com/journals/jama/fullarticle/2755841>
 65. Matthews KA, Gibson CJ, El Khoudary SR, Thurston RC. Changes in cardiovascular risk factors by hysterectomy status with and without oophorectomy: Study of Women's Health Across the Nation. *J Am Coll Cardiol*. 2013;62:191–200. doi: 10.1016/j.jacc.2013.04.042
 66. Appiah D, Schreiner PJ, Bower JK, Sternfeld B, Lewis CE, Wellons MF. Is surgical menopause associated with future levels of cardiovascular risk factor independent of antecedent levels? The CARDIA Study. *Am J Epidemiol*. 2015;182:991–999. doi: 10.1093/aje/kww162
 67. Son MK, Lim NK, Lim JY, Cho J, Chang Y, Ryu S, Cho MC, Park HY. Difference in blood pressure between early and late menopausal transition was significant in healthy Korean women. *BMC Womens Health*. 2015;15:64. doi: 10.1186/s12905-015-0219-9
 68. Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. *Am J Epidemiol*. 2009;169:1352–1361. doi: 10.1093/aje/kwp043
 69. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Progression rates of carotid intima-media thickness and adventitial diameter during the menopausal transition. *Menopause*. 2013;20:8–14. doi: 10.1097/gme.0b013e3182611787
 70. Khan ZA, Janssen I, Mazzairelli JK, Powell LH, Dumasius A, Everson-Rose SA, Barinas-Mitchell E, Matthews K, El Khoudary SR, Weinstock PJ, et al. Serial studies in subclinical atherosclerosis during menopausal transition (from the Study of Women's Health Across the Nation). *Am J Cardiol*. 2018;122:1161–1168. doi: 10.1016/j.amjcard.2018.06.039
 71. Thurston RC, Bhasin S, Chang Y, Barinas-Mitchell E, Matthews KA, Jasuja R, Santoro N. Reproductive hormones and subclinical cardiovascular disease in midlife women. *J Clin Endocrinol Metab*. 2018;103:3070–3077. doi: 10.1210/je.2018-00579
 72. El Khoudary SR, Wildman RP, Matthews K, Thurston RC, Bromberger JT, Sutton-Tyrrell K. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. *Atherosclerosis*. 2012;225:180–186. doi: 10.1016/j.atherosclerosis.2012.07.025
 73. El Khoudary SR, Santoro N, Chen HY, Tepper PG, Brooks MM, Thurston RC, Janssen I, Harlow SD, Barinas-Mitchell E, Selzer F, et al. Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause. *Eur J Prev Cardiol*. 2016;23:694–703. doi: 10.1177/2047487315607044
 74. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. *Circulation*. 2008;118:1234–1240. doi: 10.1161/CIRCULATIONAHA.108.776823
 75. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA. Hot flashes and carotid intima media thickness among midlife women. *Menopause*. 2011;18:352–358. doi: 10.1097/gme.0b013e3181fa27fd
 76. Thurston RC, El Khoudary SR, Tepper PG, Jackson EA, Joffe H, Chen HY, Matthews KA. Trajectories of vasomotor symptoms and carotid intima media thickness in the Study of Women's Health Across the Nation. *Stroke*. 2016;47:12–17. doi: 10.1161/STROKEAHA.115.010600
 77. Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, Kavousi M, Franco OH. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. *PLoS One*. 2016;11:e0157417. doi: 10.1371/journal.pone.0157417
 78. Hall MH, Okun ML, Sowers M, Matthews KA, Kravitz HM, Hardin K, Buysse DJ, Bromberger JT, Owens JF, Karpov I, et al. Sleep is associated with the metabolic syndrome in a multi-ethnic cohort of midlife women: the SWAN Sleep Study. *Sleep*. 2012;35:783–790. doi: 10.5665/sleep.1874
 79. Thurston RC, Chang Y, von Känel R, Barinas-Mitchell E, Jennings JR, Hall MH, Santoro N, Buysse DJ, Matthews KA. Sleep characteristics and carotid atherosclerosis among midlife women. *Sleep*. 2017;40:zsw052. doi: 10.1093/sleep/zsw052
 80. Matthews KA, Everson-Rose SA, Kravitz HM, Lee L, Janssen I, Sutton-Tyrrell K. Do reports of sleep disturbance relate to coronary and aortic calcification in healthy middle-aged women? Study of Women's Health Across the Nation. *Sleep Med*. 2013;14:282–287. doi: 10.1016/j.sleep.2012.11.016
 81. Zhou Y, Yang R, Li C, Tao M. Sleep disorder, an independent risk associated with arterial stiffness in menopause. *Sci Rep*. 2017;7:1904. doi: 10.1038/s41598-017-01489-7
 82. Makarem N, St-Onge MP, Liao M, Lloyd-Jones DM, Aggarwal B. Association of sleep characteristics with cardiovascular health among women and differences by race/ethnicity and menopausal status: findings from the American Heart Association Go Red for Women Strategically Focused Research Network. *Sleep Health*. 2019;5:501–508. doi: 10.1016/j.sleh.2019.05.005
 83. Janssen I, Powell LH, Matthews KA, Cursio JF, Hollenberg SM, Sutton-Tyrrell K, Bromberger JT, Everson-Rose SA; SWAN Study. Depressive symptoms are related to progression of coronary calcium in midlife women: the Study of Women's Health Across the Nation (SWAN) Heart Study. *Am Heart J*. 2011;161:1186–1191.e1. doi: 10.1016/j.ahj.2011.03.017
 84. Janssen I, Powell LH, Matthews KA, Jasielec MS, Hollenberg SM, Bromberger JT, Sutton-Tyrrell K, Everson-Rose SA. Relation of persistent depressive symptoms to coronary artery calcification in women aged 46 to 59 years. *Am J Cardiol*. 2016;117:1884–1889. doi: 10.1016/j.amjcard.2016.03.035
 85. Wassertheil-Smolter S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B, Robbins J, Aragaki A, Dunbar-Jacob J. Depression and cardiovascular sequelae in postmenopausal women: the Women's Health Initiative (WHI). *Arch Intern Med*. 2004;164:289–298. doi: 10.1001/archinte.164.3.289
 86. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, Sutton-Tyrrell K. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? *J Am Coll Cardiol*. 2009;54:2366–2373. doi: 10.1016/j.jacc.2009.10.009
 87. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. *Arch Intern Med*. 2008;168:1568–1575. doi: 10.1001/archinte.168.14.1568
 88. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. *Human Reproduction*. 2007;13:559–565.
 89. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study: the Melbourne Women's Midlife Health Project. *Climacteric*. 2004;7:375–389. doi: 10.1080/13697130400012163
 90. Guthrie JR, Ball M, Dudley EC, Garamszegi CV, Wahlqvist ML, Dennerstein L, Burger HG. Impaired fasting glycaemia in middle-aged women: a prospective study. *Int J Obes Relat Metab Disord*. 2001;25:646–651. doi: 10.1038/sj.ijo.0801569

91. Davis SR, Castelo-Branco C, Chedraui P, Lumsden MA, Nappi RE, Shah D, Villaseca P; Writing Group of the International Menopause Society for World Menopause Day 2012. Understanding weight gain at menopause. *Climacteric*. 2012;15:419–429. doi: 10.3109/13697137.2012.707385
92. Freeman EW, Sammel MD. Methods in a longitudinal cohort study of late reproductive age women: the Penn Ovarian Aging Study (POAS). *Womens Midlife Health*. 2016;2:1. doi: 10.1186/s40695-016-0014-2
93. Thomas AJ, Mitchell ES, Woods NF. The challenges of midlife women: themes from the Seattle Midlife Women's Health Study. *Womens Midlife Health*. 2018;4:8. doi: 10.1186/s40695-018-0039-9
94. Gurka MJ, Vishnu A, Santen RJ, DeBoer MD. Progression of metabolic syndrome severity during the menopausal transition. *J Am Heart Assoc*. 2016;5:e003609. doi: 10.1161/JAHA.116.003609
95. Chavarro JE, Rich-Edwards JW, Gaskins AJ, Farland LV, Terry KL, Zhang C, Missmer SA. Contributions of the Nurses' Health Studies to reproductive health research. *Am J Public Health*. 2016;106:1669–1676. doi: 10.2105/AJPH.2016.303350
96. Bao Y, Bertola ML, Lenart EB, Stampfer MJ, Willett WC, Speizer FE, Chavarro JE. Origin, methods, and evolution of the three Nurses' Health Studies. *Am J Public Health*. 2016;106:1573–1581. doi: 10.2105/AJPH.2016.303338
97. Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Hu FB, Manson JE. Exogenous hormone use: oral contraceptives, postmenopausal hormone therapy, and health outcomes in the Nurses' Health Study. *Am J Public Health*. 2016;106:1631–1637. doi: 10.2105/AJPH.2016.303349
98. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. *Diabetes Obes Metab*. 2006;8:538–554. doi: 10.1111/j.1463-1326.2005.00545.x
99. Banack HR, Wactawski-Wende J, Hovey KM, Stokes A. Is BMI a valid measure of obesity in postmenopausal women? *Menopause*. 2018;25:307–313. doi: 10.1097/GME.0000000000000989
100. Thurston RC, Karvonen-Gutierrez CA, Derby CA, El Khoudary SR, Kravitz HM, Manson JE. Menopause versus chronologic aging: their roles in women's health. *Menopause*. 2018;25:849–854. doi: 10.1097/GME.0000000000001143
101. El Khoudary SR. HDL and the menopause. *Curr Opin Lipidol*. 2017;28:328–336. doi: 10.1097/MOL.0000000000000432
102. El Khoudary SR, Wang L, Brooks MM, Thurston RC, Derby CA, Matthews KA. Increase HDL-C level over the menopausal transition is associated with greater atherosclerotic progression. *J Clin Lipidol*. 2016;10:962–969. doi: 10.1016/j.jacl.2016.04.008
103. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. *Clin Chem*. 2011;57:392–410. doi: 10.1373/clinchem.2010.155333
104. Lejsková M, Alušík S, Valenta Z, Adámková S, Piha J. Natural postmenopause is associated with an increase in combined cardiovascular risk factors. *Physiol Res*. 2012;61:587–596. doi: 10.33549/physiolres.932313
105. Samargandy S, Matthews KA, Brooks MM, Barinas-Mitchell E, Magnani JW, Janssen I, Hollenberg SM, El Khoudary SR. Arterial stiffness accelerates within 1 year of the final menstrual period: the SWAN Heart Study. *Arterioscler Thromb Vasc Biol*. 2020;40:1001–1008. doi: 10.1161/ATVBAHA.119.313622
106. Matthews KA, Abrams B, Crawford S, Miles T, Neer R, Powell LH, Wesley D. Body mass index in mid-life women: relative influence of menopause, hormone use, and ethnicity. *Int J Obes Relat Metab Disord*. 2001;25:863–873. doi: 10.1038/sj.ijo.0801618
107. Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, Cauley JA, Finkelstein JS, Jiang SF, Karlamangla AS. Changes in body composition and weight during the menopause transition. *JCI Insight*. 2019;4:e124865. doi: 10.1172/jci.insight.124865
108. Franklin RM, Ploutz-Snyder L, Kanaley JA. Longitudinal changes in abdominal fat distribution with menopause. *Metabolism*. 2009;58:311–315. doi: 10.1016/j.metabol.2008.09.030
109. Abdunour J, Doucet E, Brochu M, Lavoie JM, Strychar I, Rabasa-Lhoret R, Prud'homme D. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. *Menopause*. 2012;19:760–767. doi: 10.1097/gme.0b013e318240f6f3
110. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. *Arch Intern Med*. 1991;151:1842–1847.
111. Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X, Yosef M, Symons J. Changes in body composition in women over six years at midlife: ovarian and chronological aging. *J Clin Endocrinol Metab*. 2007;92:895–901. doi: 10.1210/jc.2006-1393
112. Iacobellis G, Gao YJ, Sharma AM. Do cardiac and perivascular adipose tissue play a role in atherosclerosis? *Curr Diab Rep*. 2008;8:20–24. doi: 10.1007/s11892-008-0005-2
113. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, O'Donnell CJ, Fox CS. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. *Circulation*. 2008;117:605–613. doi: 10.1161/CIRCULATIONAHA.107.743062
114. El Khoudary SR, Shields KJ, Janssen I, Hanley C, Budoff MJ, Barinas-Mitchell E, Everson-Rose SA, Powell LH, Matthews KA. Cardiovascular fat, menopause, and sex hormones in women: the SWAN Cardiovascular Fat Ancillary Study. *J Clin Endocrinol Metab*. 2015;100:3304–3312. doi: 10.1210/JC.2015-2110
115. El Khoudary SR, Zhao Q, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman SM, Cedars MI, Hopkins PN, et al. Effects of hormone therapy on heart fat and coronary artery calcification progression: secondary analysis from the KEEPS trial. *J Am Heart Assoc*. 2019;8:e012763. doi: 10.1161/JAHA.119.012763
116. El Khoudary SR, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman M, Hodis HN, Brinton EA, Miller VM, et al. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: the KEEPS trial. *Menopause*. 2020;27:255–262. doi: 10.1097/GME.0000000000001472
117. Venetsanaki V, Polyzos SA. Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic perspectives. *Curr Vasc Pharmacol*. 2019;17:546–555. doi: 10.2174/1570161116666180711121949
118. Turolo E, Petta S, Vanni E, Milosa F, Valenti L, Critelli R, Miele L, Maccio L, Calvaruso V, Fracanzani AL, et al. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. *Dis Model Mech*. 2015;8:1037–1046. doi: 10.1242/dmm.019950
119. Veronese N, Notarnicola M, Osella AR, Cisternino AM, Reddavid R, Inguaggiato R, Guerra V, Rotolo O, Zinzi I, Chiloiro M, et al. Menopause does not affect fatty liver severity in women: a population study in a Mediterranean area. *Endocr Metab Immune Disord Drug Targets*. 2018;18:513–521. doi: 10.2174/1871530318666180423101755
120. Park SH, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, et al. Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women. *Climacteric*. 2020;23:173–177. doi: 10.1080/13697137.2019.1650018
121. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, et al; on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation*. 2010;121:586–613. doi: 10.1161/CIRCULATIONAHA.109.192703
122. *Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities*. Hyattsville, MD: National Center for Health Statistics; 2016.
123. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States, 2011–2014. *NCHS Data Brief*. 2015:1–8.
124. McTigue KM, Chang YF, Eaton C, Garcia L, Johnson KC, Lewis CE, Liu S, Mackey RH, Robinson J, Rosal MC, et al. Severe obesity, heart disease, and death among white, African American, and Hispanic postmenopausal women. *Obesity (Silver Spring)*. 2014;22:801–810. doi: 10.1002/oby.20224
125. Sun Y, Liu B, Snetelaar LG, Wallace RB, Caan BJ, Rohan TE, Neuhauser ML, Shadyab AH, Chlebowski RT, Manson JE, et al. Association of normal-weight central obesity with all-cause and cause-specific mortality among postmenopausal women. *JAMA Netw Open*. 2019;2:e197337. doi: 10.1001/jamanetworkopen.2019.7337
126. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann Smith C, Wilkins E, Rayner M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. *J Am Heart Assoc*. 2016;5:e002495. doi: 10.1161/JAHA.115.002495
127. 2018 Physical Activity Guidelines Advisory Committee. *2018 Physical Activity Guidelines Advisory Committee Scientific Report*. Washington, DC: US Department of Health and Human Services. 2018.

128. Wang D, Jackson EA, Karvonen-Gutierrez CA, Elliott MR, Harlow SD, Hood MM, Derby CA, Sternfeld B, Janssen I, Crawford SL, et al. Healthy lifestyle during the midlife is prospectively associated with less subclinical carotid atherosclerosis: the Study of Women's Health Across the Nation. *J Am Heart Assoc*. 2018;7:e010405. doi: 10.1161/JAHA.118.010405
129. Patterson R, McNamara E, Tainio M, de Sá TH, Smith AD, Sharp SJ, Edwards P, Woodcock J, Brage S, Wijndaele K. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. *Eur J Epidemiol*. 2018;33:811–829. doi: 10.1007/s10654-018-0380-1
130. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, Hartge P, Gapstur SM. 50-Year trends in smoking-related mortality in the United States. *N Engl J Med*. 2013;368:351–364. doi: 10.1056/NEJMsa1211127
131. Hackshaw A, Morris JK, Boniface S, Tang JL, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. *BMJ*. 2018;360:j5855. doi: 10.1136/bmj.j5855
132. Colpani V, Baena CP, Jaspers L, van Dijk GM, Farajzadegan Z, Dhana K, Tielemans MJ, Voortman T, Freak-Poli R, Veloso GGV, et al. Lifestyle factors, cardiovascular disease and all-cause mortality in middle-aged and elderly women: a systematic review and meta-analysis. *Eur J Epidemiol*. 2018;33:831–845. doi: 10.1007/s10654-018-0374-z
133. van Eekelen E, Geelen A, Alsema M, Lamb HJ, de Roos A, Rosendaal FR, de Mutsert R. Sweet snacks are positively and fruits and vegetables are negatively associated with visceral or liver fat content in middle-aged men and women. *J Nutr*. 2019;149:304–313. doi: 10.1093/jn/nxy260
134. Wenger NK, Arnold A, Bairey Merz CN, Cooper-DeHoff RM, Ferdinand KC, Fleg JL, Gulati M, Isiadino I, Itchhaporia D, Light-McGroary K, et al. Hypertension across a woman's life cycle. *J Am Coll Cardiol*. 2018;71:1797–1813. doi: 10.1016/j.jacc.2018.02.033
135. Di Giosia P, Giorgini P, Stamerra CA, Petrarca M, Ferri C, Sahebkar A. Gender differences in epidemiology, pathophysiology, and treatment of hypertension. *Curr Atheroscler Rep*. 2018;20:13. doi: 10.1007/s11883-018-0716-z
136. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. *NCHS Data Brief*. 2017;1–8.
137. Peters SA, Huxley RR, Woodward M. Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. *Stroke*. 2013;44:2394–2401. doi: 10.1161/STROKEAHA.113.001624
138. Zhao M, Vaartjes I, Graham I, Grobbee D, Spiering W, Klipstein-Grobusch K, Woodward M, Peters SA. Sex differences in risk factor management of coronary heart disease across three regions. *Heart*. 2017;103:1587–1594. doi: 10.1136/heartjnl-2017-311429
139. Dong X, Cai R, Sun J, Huang R, Wang P, Sun H, Tian S, Wang S. Diabetes as a risk factor for acute coronary syndrome in women compared with men: a meta-analysis, including 10 856 279 individuals and 106 703 acute coronary syndrome events [published online February 23, 2017]. *Diabetes Metab Res Rev*. doi: 10.1002/dmrr.2887. <https://onlinelibrary.wiley.com/doi/abs/10.1002/dmrr.2887>
140. Słopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremek JD, Cano A, Chedraui P, Goulis DG, Lopes P, et al. Menopause and diabetes: EMAS clinical guide. *Maturitas*. 2018;117:6–10. doi: 10.1016/j.maturitas.2018.08.009
141. Peters SA, Huxley RR, Sattar N, Woodward M. Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. *Curr Cardiovasc Risk Rep*. 2015;9:36. doi: 10.1007/s12170-015-0462-5
142. Sacco RL. The new American Heart Association 2020 goal: achieving ideal cardiovascular health. *J Cardiovasc Med (Hagerstown)*. 2011;12:255–257. doi: 10.2459/JCM.0b013e328343e986
143. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. *N Engl J Med*. 1997;336:1117–1124. doi: 10.1056/NEJM199704173361601
144. Van Horn L, Carson JA, Appel LJ, Burke LE, Economos C, Karmally W, Lancaster K, Lichtenstein AH, Johnson RK, Thomas RJ, et al; on behalf of the American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association [published correction appears in *Circulation*. 2016;134:e534]. *Circulation*. 2016;134:e505–e529. doi: 10.1161/CIR.0000000000000462
145. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in *Circulation*. 2014;129(suppl 2):S100–S101 and *Circulation*. 2015;131:e326]. *Circulation*. 2014;129(suppl 2):S76–S99. doi: 10.1161/01.cir.0000437740.48606.d1
146. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [published correction appears in *Circulation*. 2014;129(suppl 2):S139–S140]. *Circulation*. 2014;129(suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee
147. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. *N Engl J Med*. 1991;325:461–466. doi: 10.1056/NEJM199108153250703
148. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. *N Engl J Med*. 1998;339:12–20. doi: 10.1056/NEJM199807023390103
149. Kuller LH, Simkin-Silverman LR, Wing RR, Meilahn EN, Ives DG. Women's Healthy Lifestyle Project: a randomized clinical trial: results at 54 months. *Circulation*. 2001;103:32–37. doi: 10.1161/01.cir.103.1.32
150. Wildman RP, Schott LL, Brockwell S, Kuller LH, Sutton-Tyrrell K. A dietary and exercise intervention slows menopause-associated progression of subclinical atherosclerosis as measured by intima-media thickness of the carotid arteries. *J Am Coll Cardiol*. 2004;44:579–585. doi: 10.1016/j.jacc.2004.03.078
151. Deibert P, König D, Vitolins MZ, Landmann U, Frey I, Zahradnik HP, Berg A. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. *Nutr J*. 2007;6:31. doi: 10.1186/1475-2891-6-31
152. Yeh ML, Liao RW, Hsu CC, Chung YC, Lin JG. Exercises improve body composition, cardiovascular risk factors and bone mineral density for menopausal women: a systematic review and met analysis of randomized controlled trials. *Appl Nurs Res*. 2018;40:90–98. doi: 10.1016/j.apnr.2017.12.011
153. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. *N Engl J Med*. 2000;343:16–22. doi: 10.1056/NEJM200007063430103
154. McVay MA, Copeland AL. Smoking cessation in peri- and postmenopausal women: a review. *Exp Clin Psychopharmacol*. 2011;19:192–202. doi: 10.1037/a0023119
155. Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P, Fraser C, MacLennan G. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. *BMJ*. 2017;359:j4849. doi: 10.1136/bmj.j4849
156. Yu E, Malik VS, Hu FB. Cardiovascular disease prevention by diet modification. *JACC Health Promotion Series*. *J Am Coll Cardiol*. 2018;72:914–926. doi: 10.1016/j.jacc.2018.02.085
157. Ward E, Gold EB, Johnson WO, Ding F, Chang PY, Song P, El Khoudary SR, Karvonen-Gutierrez C, Ylitalo KR, Lee JS. Patterns of cardiometabolic health as midlife women transition to menopause: a prospective multiethnic study. *J Clin Endocrinol Metab*. 2019;104:1404–1412. doi: 10.1210/clinem.2018-00941
158. US Department of Health and Human Services. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms: recommendations for clinical evaluation. January 2003. <https://www.fda.gov/media/71359/download>. Accessed January 9, 2020.
159. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. *JAMA*. 1991;265:1861–1867.

160. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. *Prev Med.* 1991;20:47–63. doi: 10.1016/0091-7435(91)90006-p
161. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, et al. Postmenopausal hormone therapy and mortality. *N Engl J Med.* 1997;336:1769–1775. doi: 10.1056/NEJM199706193362501
162. Sullivan JM, Vander Zwaag R, Lemp GF, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Postmenopausal estrogen use and coronary atherosclerosis. *Ann Intern Med.* 1988;108:358–363. doi: 10.7326/0003-4819-108-3-358
163. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. *Am Heart J.* 1988;115:954–963. doi: 10.1016/0002-8703(88)90063-4
164. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JO. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. *Am Heart J.* 1989;117:1209–1214. doi: 10.1016/0002-8703(89)90398-0
165. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA.* 1998;280:605–613. doi: 10.1001/jama.280.7.605
166. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. *N Engl J Med.* 2001;345:1243–1249. doi: 10.1056/NEJMoa010534
167. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. *N Engl J Med.* 1985;313:1044–1049. doi: 10.1056/NEJM198510243131703
168. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med.* 2002;349:523–534. doi: 10.1056/NEJMoa030808
169. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, et al; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. *Arch Intern Med.* 2006;166:357–365. doi: 10.1001/archinte.166.3.357
170. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. *JAMA.* 2003;289:2673–2684. doi: 10.1001/jama.289.20.2673
171. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA.* 2004;291:1701–1712. doi: 10.1001/jama.291.14.1701
172. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *JAMA.* 2013;310:1353–1368. doi: 10.1001/jama.2013.278040
173. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, et al; WHI Investigators. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. *JAMA.* 2017;318:927–938. doi: 10.1001/jama.2017.11217
174. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, Køber L, Jensen JE. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. *BMJ.* 2012;345:e6409. doi: 10.1136/bmj.e6409
175. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. *Am J Med.* 2009;122:1016–1022.e1. doi: 10.1016/j.amjmed.2009.05.021
176. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. *J Gen Intern Med.* 2006;21:363–366. doi: 10.1111/j.1525-1497.2006.00389.x
177. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. *J Gen Intern Med.* 2004;19:791–804. doi: 10.1111/j.1525-1497.2004.30281.x
178. Boardman HM, Hartley L, Eisinga A, Main C, Roque I, Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev.* 2015:CD002229. doi: 10.1002/14651858.CD002229.pub4
179. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. *Am J Med.* 2009;122:42–52.e2. doi: 10.1016/j.amjmed.2008.07.026
180. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. *Menopause.* 2015;22:976–983. doi: 10.1097/GME.0000000000000450
181. Tremollieres FA, Cigagna F, Alquier C, Cauneille C, Pouilles J, Ribot C. Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. *Atherosclerosis.* 2000;153:81–88. doi: 10.1016/s0021-9150(00)00372-5
182. Takahashi K, Tanaka E, Murakami M, Mori-Abe A, Kawagoe J, Takata K, Ohmichi M, Kurachi H. Long-term hormone replacement therapy delays the age related progression of carotid intima-media thickness in healthy postmenopausal women. *Maturitas.* 2004;49:170–177. doi: 10.1016/j.maturitas.2004.01.003
183. McGrath BP, Liang YL, Teede H, Shiel LM, Cameron JD, Dart A. Age-related deterioration in arterial structure and function in postmenopausal women: impact of hormone replacement therapy. *Arterioscler Thromb Vasc Biol.* 1998;18:1149–1156. doi: 10.1161/01.atv.18.7.1149
184. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu CR, Liu CH, Azen SP; Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 2001;135:939–953. doi: 10.7326/0003-4819-135-11-200112040-00005
185. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. *Ann Intern Med.* 2014;161:249–260. doi: 10.7326/M14-0353
186. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, et al; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. *N Engl J Med.* 2016;374:1221–1231. doi: 10.1056/NEJMoa1505241
187. Ostberg JE, Story C, Donald AE, Attar MJ, Halcox JP, Conway GS. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. *Clin Endocrinol (Oxf).* 2007;66:557–564. doi: 10.1111/j.1365-2265.2007.02772.x
188. Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, Kaunitz AM, Lakshminarayan K, Martin LW, Phillips LS, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. *Menopause.* 2014;21:260–266. doi: 10.1097/GME.0b013e31829a64f9
189. Simon JA, Laliberté F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. *Menopause.* 2016;23:600–610. doi: 10.1097/GME.0000000000000590
190. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ.* 2019;364:k4810. doi: 10.1136/bmj.k4810
191. Chen Z, Bassford T, Green SB, Cauley JA, Jackson RD, LaCroix AZ, Leboff M, Stefanick ML, Margolis KL. Postmenopausal hormone therapy and body composition: a substudy of the estrogen plus progestin trial of the Women's Health Initiative. *Am J Clin Nutr.* 2005;82:651–656. doi: 10.1093/ajcn.82.3.651
192. Espeland MA, Stefanick ML, Kritz-Silverstein D, Fineberg SE, Waclawiw MA, James MK, Greendale GA. Effect of postmenopausal hormone therapy on body weight and waist and hip girths: Postmenopausal Estrogen-Progestin Interventions Study Investigators. *J Clin Endocrinol Metab.* 1997;82:1549–1556. doi: 10.1210/jcem.82.5.3925
193. Cintron D, Beckman JP, Bailey KR, Lahr BD, Jayachandran M, Miller VM. Plasma orexin A levels in recently menopausal women during and 3

- years following use of hormone therapy. *Maturitas*. 2017;99:59–65. doi: 10.1016/j.maturitas.2017.01.016
194. Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, Elbaz A, Scarabin PY. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. *Stroke*. 2016;47:1734–1741. doi: 10.1161/STROKEAHA.116.013052
 195. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 2003;138:1–9. doi: 10.7326/0003-4819-138-1-200301070-00005
 196. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, et al; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. *N Engl J Med*. 2007;356:2591–2602. doi: 10.1056/NEJMoa071513
 197. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. *J Clin Endocrinol Metab*. 2015;100:4588–4594. doi: 10.1210/jc.2015-1864
 198. Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. *Menopause*. 2018;25:375–379. doi: 10.1097/GME.0000000000001023
 199. NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. *Menopause*. 2017;24:728–753. doi: 10.1097/GME.0000000000000921
 200. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. *Climacteric*. 2016;19:109–150. doi: 10.3109/13697137.2015.1129166
 201. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015;100:3975–4011. doi: 10.1210/jc.2015-2236
 202. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in *Circulation*. 2019;139:e1182–1186]. *Circulation*. 2019;139:e1082–e1143. doi: 10.1161/CIR.0000000000000625
 203. Khan SU, Khan MU, Riaz H, Valavoor S, Zhao D, Vaughan L, Okunrintemi V, Riaz IB, Khan MS, Kaluski E, et al. Effects of nutritional supplements and dietary interventions on cardiovascular outcomes: an umbrella review and evidence map. *Ann Intern Med*. 2019;171:190–198. doi: 10.7326/M19-0341
 204. Hooper L, Al-Khudairy L, Abdelhamid AS, Rees K, Brainard JS, Brown TJ, Ajabnoor SM, O'Brien AT, Winstanley LE, Donaldson DH, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2018;11:CD011094. doi: 10.1002/14651858.CD011094.pub4
 205. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. *Circulation*. 2010;121:1069–1077. doi: 10.1161/CIRCULATIONAHA.109.906479
 206. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushi T, Teramoto T, Uchiyama S, Nakamura H; for the MEGA Study Group. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). *Circulation*. 2008;117:494–502. doi: 10.1161/CIRCULATIONAHA.106.671826
 207. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374:2021–2031. doi: 10.1056/NEJMoa1600176
 208. Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. *Int J Cardiol*. 2010;138:25–31. doi: 10.1016/j.ijcard.2008.08.001
 209. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*. 2009;338:b2376. doi: 10.1136/bmj.b2376
 210. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet*. 2015;385:1397–1405.
 211. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. *JAMA*. 2004;291:2243–2252. doi: 10.1001/jama.291.18.2243
 212. Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E; Ezetimibe Study Group. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. *J Womens Health (Larchmt)*. 2004;13:1101–1107. doi: 10.1089/jwh.2004.13.1101
 213. Guo W, Fu J, Chen X, Gao B, Fu Z, Fan H, Cui Q, Zhu X, Zhao Y, Yang T, et al. The effects of estrogen on serum level and hepatocyte expression of PCSK9. *Metabolism*. 2015;64:554–560. doi: 10.1016/j.metabol.2015.01.009
 214. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. *J Clin Endocrinol Metab*. 2009;94:2537–2543. doi: 10.1210/jc.2009-0141
 215. Jeenduang N. Circulating PCSK9 concentrations are increased in postmenopausal women with the metabolic syndrome. *Clin Chim Acta*. 2019;494:151–156. doi: 10.1016/j.cca.2019.04.067
 216. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. *JAMA*. 2019;322:1780–1788. doi: 10.1001/jama.2019.16585
 217. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. *Circulation*. 1997;96:2468–2482. doi: 10.1161/01.cir.96.7.2468
 218. Mosca L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson TA, Redberg RF, Smith SC Jr, Winston M, Zinberg S. Guide to preventive cardiology for women: AHA/ACC Scientific Statement Consensus Panel statement. *Circulation*. 1999;99:2480–2484. doi: 10.1161/01.cir.99.18.2480
 219. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143–3421.
 220. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Stroobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, et al. Evidence-based guidelines for cardiovascular disease prevention in women. *Circulation*. 2004;109:672–693. doi: 10.1161/01.CIR.0000114834.85476.81
 221. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, et al; for the Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation*. 2007;115:1481–1501. doi: 10.1161/CIRCULATIONAHA.107.181546
 222. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. *Lancet*. 1999;353:89–92. doi: 10.1016/S0140-6736(98)10279-9
 223. Sibley C, Blumenthal RS, Merz CN, Mosca L. Limitations of current cardiovascular disease risk assessment strategies in women. *J Womens Health (Larchmt)*. 2006;15:54–56. doi: 10.1089/jwh.2006.15.54
 224. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117:743–753. doi: 10.1161/CIRCULATIONAHA.107.699579
 225. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. 2007;297:611–619. doi: 10.1001/jama.297.6.611

226. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, et al; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association [published corrections appear in *Stroke*. 2014;45:e95 and *Stroke*. 2014;45:e214]. *Stroke*. 2014;45:1545–1588. doi: 10.1161/01.str.0000442009.06663.48
227. Lisabeth L, Bushnell C. Stroke risk in women: the role of menopause and hormone therapy. *Lancet Neurol*. 2012;11:82–91. doi: 10.1016/S1474-4422(11)70269-1
228. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. *Menopause*. 2012;19:272–277. doi: 10.1097/gme.0b013e31822a9937
229. McSweeney JC, Rosenfeld AG, Abel WM, Braun LT, Burke LE, Daugherty SL, Fletcher GF, Gulati M, Mehta LS, Pettey C, et al; on behalf of the American Heart Association Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Hypertension, Council on Lifestyle and Cardiometabolic Health, and Council on Quality of Care and Outcomes Research. Preventing and experiencing ischemic heart disease as a woman: state of the science: a scientific statement from the American Heart Association. *Circulation*. 2016;133:1302–1331. doi: 10.1161/CIR.0000000000000381
230. Olszanecka A, Pośnik-Urbańska A, Kawecka-Jaszcz K, Czarnecka D, Fedak D. Adipocytokines and blood pressure, lipids and glucose metabolism in hypertensive perimenopausal women. *Kardiol Pol*. 2010;68:753–760.
231. Tikhonoff V, Casiglia E, Gasparotti F, Spinella P. The uncertain effect of menopause on blood pressure. *J Hum Hypertens*. 2019;33:421–428. doi: 10.1038/s41371-019-0194-y
232. Shifren JL, Gass ML; NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. *Menopause*. 2014;21:1038–1062. doi: 10.1097/GME.0000000000000319
233. Finkelstein JS, Lee H, Karlamangla A, et al. Antimüllerian hormone and impending menopause in late reproductive age: the Study of Women's Health Across the Nation. *J Clin Endocrinol Metab*. 2020;105:e1862–e1871. doi: 10.1210/clinem/dgz283